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ABSTRACT 
The typical progression of normal breast tissue to an invasive breast carcinoma 
involves a series of steps that include an increase in the number of breast cells 
(hyperplasia), an increase in the number of abnormal cells (atypical hyperplasia) and then 
the development of an in situ carcinoma. An in situ carcinoma means that cancer is 
present but it still confined to the site where the abnormal growth originally developed, 
the ducts (ductal carcinoma in situ) or the lobules (lobular carcinoma in situ). The cancer 
cells that comprise this in situ cancer can then undergo further changes allowing them to 
become invasive and spread into the surrounding tissues. In situ carcinomas are often 
referred to as pre-cancerous since individuals who are diagnosed with having such are at 
an increased risk for developing breast carcinoma. 
The incidence of breast cancer is increasing across Canada, which is suspected 
to be a result of an increase in mammographic screening. This often translates into 
detection of the carcinoma in its earliest stages when the treatment response is optimal 
and the prognosis is more favorable. However, for many, the cancer is advanced and 
therefore may have limited treatment options. Also, there are individuals who have the 
option of treatment upon diagnosis, and still unfortunately have a high likelihood of 
recurrence. Yet again, there are individuals for whom the cancer is found in the early 
stages, but have a short disease-free period following treatment. In such cases, it may be 
that the tumor(s) is resistant to the treatment they received. For all of these reasons there 
is a need for improved screening methods, improved prognostic indicators and improved 
therapeutic regimes. 
Estrogen receptor-alpha (ERa) is one of the steroid hormone receptors that 
plays a role in normal growth and development of the breast; it has also long been 
implicated in breast tumorigenesis. Many of the current breast cancer treatments target 
the action of the estrogen receptor (ER) indirectly; by blocking either the ability of the ER 
ligand, estrogen, from binding to the receptor or the synthesis of estrogen. Hence, ERa 
expression could potentially guide physicians in predicting prognosis and devising a 
treatment plan. 
In an effort to improve upon current standard treatments or devise new, more 
efficacious therapies, the molecular pathway of ERa needs to be resolved. Human 
mesoderm induction early response 1 (hMI-ERI) is a key regulator ofthis pathway 
through its interaction with ERa. During investigations into the role of fibroblast growth 
factors (FGFs) in the development and differentiation of Xenopus laevis embryo, MI-ERl 
was found to be an initial target of the FGF signal transduction pathway. 
The hmi-er 1 gene was cloned and characterized (Paterno et. a!., 1998) and 
shown to have two major protein isoforms, hMI-ERla and hMI-ERl~. Both isoforms 
contain a number of motifs characteristic of transcriptional regulators and have been 
shown to act as repressors of transcription (Paterno, et. a!. , 1997; Ding, et. a!. , 2003; 
Ding, et. al. , 2004). The alpha and beta isoforms differ in their C-terminus. hMI-ERla 
contains a classic nuclear hormone receptor (NR) co-regulator motif, an LXXLL domain, 
which is not found within the beta isoform. 
MI-ER 1 a has been shown to interact with ERa in breast cancer cells, in the 
presence and absence of estrogen. It was also found to reduce ER-mediated breast cell 
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growth in ER-positive breast cancer cells (McCarthy, et. al., 2008). Theoretically, this 
data supports a role for MI-ERla in breast cancer cell proliferation. 
My hypothesis is that MI-ERla might be differentially expressed in normal 
breast tissue and breast carcinoma. Immunohistochemical analysis of MI-ERa expression 
pattern and subcellular localization in both normal breast and breast carcinoma was 
carried out using 156 whole tissue sections and 771 cases from tissue microarrays. 
While there was no consistent difference in the level of expression between normal cells 
and tumor cells, there was a striking difference in the subcellular localization. In normal 
and hyperplastic breast 72% of the cases had nuclear MI-ERla, whereas in breast 
diseases only 51% ductal carcinoma in situ (DCIS), 25% invasive lobular carcinoma 
(ILC) and only 4% invasive ductal carcinoma (IDC) has nuclear MI-ERal staining 
(McCarthy,P. et. al., 2008). This represents a shift in the subcellular localization of Ml-
ERla, from nuclear to cytoplasmic, during breast cancer progression. Such a shift in MI-
ERla localization might then be associated with the progression of breast cancer; hence, 
MI-ERla might prove useful for prognostic determination. Hence, it is possible that the 
lack of nuclear MI-ERla expression in DCIS lesions will serve as a means of identifying 
women who are at a higher risk for developing invasive breast carcinoma. 
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1. I NTRODIJCT!ON 
1.1 General Introduction 
1.1.1 Canadian Cancer Incidence and Mortality Rates 
It is estimated that 166,400 Canadians will be diagnosed with some type of cancer 
in 2008, with approximately 73,800 Canadian deaths due to cancer. The 3 major types of 
cancer that constitute the new cases are prostate, lung and colorectal for males and breast, 
lung and colorectal for females (Canadian Cancer Society & National Cancer Institute of 
Canada, 2008). 
Wlllle lung cancer continues to be the leading cause of cancer mortality for 
Canadian women, breast cancer leads with respect to cancer incidence. Atlantic Canada 
and Quebec have both the highest incidence and mortality rates for all cancers. This year 
in Canada, 22,400 new cases of breast cancer and 5300 deaths as a result of breast cancer 
are estimated. Of those, 360 new cases of breast cancer are estimated for Newfoundland 
and Labrador (NL) and 100 of the total NL individuals with breast cancer are estimated to 
die from breast cancer in 2008 (Canadian Cancer Society & National Cancer Institute of 
Canada, 2008). 
Breast cancer incidence rates have increased steadily from 1979-1999, which is 
thought to be largely due to an increase in mammography screening (Canadian Cancer 
Society & National Cancer Institute of Canada, 2008). This increase in screening has lead 
to earlier detection of breast cancer and resulting in a better treatment response and a 
decrease in the national mortality rates as a result (Canadian Cancer Society & National 
Cancer Institute of Canada, 2008; Guarneri & Conte, 2004). There is a positive 
correlation between an increase in breast cancer incidence and an increase in women's 
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age; as such, its incidence rate tends to be higher among post-menopausal women. A 
women with a first-degree relative (mother, sister or daughter) who has had breast cancer, 
has an increased risk of developing breast cancer. In fact, their relative risk is 1.5-2.5 
times higher than someone not having a first degree relative who has had breast cancer. 
1.1.2 Cell Cycle Regulation and Cell Proliferation 
The cell cycle is an event that results in either cell growth or in the division of a 
single cell, through a series of sequential steps or stages referred to as the cell cycle, to 
give rise to two new daughter cells (Norbury & Nurse, 1992). Specific elements of the 
cell cycle vary from organism to organism and within a single organism. This essential 
process may also occur at different times points throughout an organism's lifetime. 
However, there are some parts of the cell cycle that are known to be universal. 
The progressional phases within the cell cycle are 0 1 phase (Gapl phase), S 
phase (Synthesis phase), 0 2 phase (Gap2 phase), M phase (Mitotic phase) (Figure I) 
(Vermeulen, Van Bockstaele, & Berneman, 2003). The first three ofthese, the 0 1 phase, 
the S phase and the 0 2 phase, as well as the 0 0 phase comprise what is known as the 
interphase of the cell cycle. For actively dividing cells, interphase can last from 12 to 24 
hours and is the fraction of the cell cycle during which the cell synthesizes its RNA, 
makes protein and grows in size. The interphase is microvisually inactive; however, on a 
molecular level it is very active (Murray & Hunt, 1993). 
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Figure 1 The cell cycle 
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Cells undergoing normal cell division, either Go (quiescent cells) or newly formed cells 
from M phase (mitotic phase), progress equentially from a period that permits growth, 
RNA and protein synthesis in G 1 (Gapl), to the S-phase (Synthesis phase) in which the 
cells genome duplicates, to a second Gap phase (G2) and then the Mitotic phase (M-
phase). During the mitotic phase the cell ' s nucleus divides in half (karyokinesis), 
followed by a physical division of the cell (cytokinesis) into two new daughter cells. 1he 
specific junctures of the cell cycle at which the activated Cdk/cyclin complexes exert 
their influences are indicated (Vermeulen et. al. , 2003). 
3 
1.1.2 Cell Cycle Regulation and Cell Proliferation (continued) 
One complete transition through all phases of the cell cycle is that which 
involves both one cycle of DNA synthesis and one round of chromosomal segregation 
followed by division to give rise to two new daughter cells. Cells which are non-dividing, 
quiescent cells, are those which are not actively progressing through the cell cycle and are 
classified as being in Go (Gap 0). This is the period when the cell has either left the cell 
cycle on a permanent basis and is no longer dividing or is in a temporary rest state 
(Lodish, 2004; Norbury & Nurse, 1992). The cell cycle begins when one of the new cells 
generated in the M phase or a cell which was in Go receives a growth or mitogenic signal 
and enters the cell cycle at G1 (Lodish, 2004; Vermeulen et al. , 2003). During G1 the cell 
grows and prepares for DNA replication inS phase. This replication of the genome 
allows for each new daughter cell to have it own copy. Once the cell passes through G2, 
the cell cycle will culminate following two micro visual events, the division of the nucleus 
(karyokinesis) and a physical division of cell ( cytokenesis) (Murray & Hunt, 1993; 
Norbury & Nurse, 1992). Since the entry into each phase is dependent on its success in 
the precedent one; a means of monitoring the accuracy exists. Before and after DNA 
synthesis, the Gap phases (G1 and G2) permit time for the cell to grow and synthesize 
both RNA and proteins. In addition, these two junctures serve as cell cycle checkpoints 
and is regarded as the decision-making period for the cell (Figure 2) (Gorbsky, 1997; 
Hartwell & Weinert, 1989; Russell, 1998). In that, G1 and G2, are the 
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intervals when the cell determines if it is ready to proceed to into the S phase and the M 
phase or if the cell will remain there to allow further growth or to repair DNA damages 
through activation ofthe DNA damage checkpoint. 
5 
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Figure 2 Check points that occur during normal cell cycle progression 
At various timepoints during normal cell cycle progression, namely 0 1/S phase 
transition, during S-phase, 0 2/M phase and during M-phase, there exists several 
checkpoints (indicated by arrows) to ensure the fidelity of DNA replication and spindle 
formation, for example. (Adapted from 
http:/ /home page. mac.com/ enognog/check point. htm) 
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1.1.2 Cell Cycle Regulation and Cell Proliferation (continued) 
Aside from these two main checkpoints, G1 and G2, two other critical checks 
occur during cell cycle progression. An intra-S phase checkpoint in theM-phase verify 
the accuracy of replication as it proceeds and the correctness of spindle formation, 
respectively (Figure 2) (Nyberg, Michelson, Putnam, & Weinert, 2002). The latter of 
which is critical during mitosis to allow for equal chromosome segregation. 
Enzymes from the Cyclin-dependent kinase (Cdk) family are those which 
predominantly direct normal progression of the cell cycle. At precise time points during 
the cell cycle, specific activities are tightly regulated through the formation of a 
heterodimer between a Cdk, which possess catalytic power and its cognate regulatory 
unit, the cyclin (Figure 1) (Collins & Garrett, 2005; Lodish, 2004; Vermeulen et al., 
2003). As such, these heterodirners can be regarded as switches that allow for the 
transition from one cell cycle juncture to another. Each of the Cdks become activated in 
the presence of a Cdk-activating kinase (CAK), which phosphorylates the cdk, thus 
inducing in it a conformational change that increases binding efficiency to cyclins 
(Carnero, 2002; Morgan, 1997; Vermeulen et al., 2003). A complex of Cdk4 or Cdk6 and 
one of the D-type cylins (Dl, D2, or D3) are responsible for entry into G1 phase of the 
cell cycle (Morgan, 1997). The Cdk2/cyclin E complex regulates transition from the latter 
phase into the S-phase of the cell cycle, whereas Cdk2 complexed with cyclin A is 
necessary for progression through the S-phase (Woo & Poon, 2003). Cdkl complexed 
with cyclin A and then cyclin B is required for the transition from G2 into the M-phase 
and during theM-phase, respectively. Once activated, a G1 phase Cdk/cyclin complex 
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such as Cdk 4/cyclin D phosphorylates its substrate, the retinoblastoma protein (RB) 
(Grana, Garriga, & Mayol, 1998; Vermeulen et al., 2003). Phosphorylated RB protein 
disrupts a complex that results in release of E2F, a potent regulator of gene 
transcription. In that, free E2F can then drive transcription of genes whose products are 
essential for advancement to and progression through the S-phase (Vermeulen et al., 
2003). 
1.1.3 Cell Cycle Control and Cancer Development 
The term cancer can be used to define, in basic terms, a disease in which an 
abnonnal population of cells (tumor) has arisen that interferes with the normal function of 
a tissue and often the system as a whole (Hanahan & Weinberg, 2000); hence, it is the 
reason why so many individuals eventually succumb to this disease. 
The three dominant features of cancerous growth include uncontrolled cell 
proliferation, an invasive phenotype (has broken through the confines of initial site of 
origin) and the potential to become metastatic (spread to another organ(s) through the 
blood and/or lymphatic system) (Hanahan & Weinberg, 2000). In contrast, a benign 
tumor is not characterized by the latter two attributes; it is a growth arising from an 
increased proliferation, but it is non-invasive and non-metastatic. However, a benign 
tumor can still impose serious health consequences (Cifone, 1982). In addition to the 
three features mentioned above, there are two other characteristics that also define an 
abnormal growth as tumorgenic, one is its ability to both promote vascularization and the 
other is its ability to escape progran1med cell death (apoptosis) (Garrett, 2001 ; Hanahan & 
Weinberg, 2000). 
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Perturbation ofthe normal cell cycle, and hence an increased probability of 
cancer development, can occur through activation of a proto-oncogene or inactivation of a 
tumor suppressor gene. A proto-oncogene is a normal gene, but when mutated or over-
expressed can give rise to a product that is tumor-promoting and is then referred to as an 
oncogene. 1 herefore, an oncogene has the potential, if it is inappropriately expressed, to 
influence the transformation of a cell from one that is normal to one that is cancerous. 
Tumor suppressor genes code for proteins that repress cell growth and/or promote cell 
death. However, when such genes are inactivated they can cause an increase in the rate of 
cell growth and cell division. 
Since many cancers occur as a result of a deregulated cell cycle, each of the 
elements involved are often the target for cancer therapeutics (Camero, 2002; 
Hennighausen & Robinson, 2005). Down-regulation or mutation of several tumor 
suppressor genes, including p53 and RB have been implicated in the development of 
breast cancer and are associated with a poor prognosis (Oliveira, Ross, & Fletcher, 2005). 
A cell can acquire genetic errors by inheriting a genetic mutation(s) and/or 
through exposure to damaging environmental agents. In the first instance, an individual 
can have an inherited genetic pattern whereby a specific segment of the genome, a gene, 
is already altered at birth. In this regard, he/she has an innate or a genetic predispositon to 
cancer. This alteration is such that it increases that individual's lifetime risk to developing 
cancer (Hodgson, 2008). Secondly, DNA is constantly exposed to environmental agents 
that create insults or mutations in the genetic code. Such damaging agents include, but are 
not limited to, exposure to both ultraviolet rays and geneotoxic chemicals such as tobacco 
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smoke, as well as free radicals that are generated during cellular metabolism (Cadet, 
Berger, Douki, & Ravanat, 1997; Hoeijmakers, 2001). 
Under normal circumstances these genetic errors will be resolved by the cell's 
DNA machinery upon detection during cell cycle checkpoints (Fantes & Brooks, 1993; 
Stein, 1998). However, both inherited or environmental mutations can occur in genes 
whose products participate in the cell cycle's DNA maintenance checkpoints. These 
include the DNA damage checkpoint and DNA replication checkpoint (Ashwell & 
Zabludoff, 2008; Nyberg et al. , 2002). When a mutation occurs in either a protein that 
initiates a DNA damage checkpoint or in a DNA repair protein itself, such as ataxia-
telangiectasia mutated (ATM) or breast cancer 1 (BRCAI), respectively, then the 
mutation can go undetected and unrepaired. Hence, in spite of the cell containing a 
genetic alteration, it continues to proliferate (Brumer & Shakhnovich, 2004; Christmann, 
Tomicic, Roos, & Kaina, 2003; McGowan & Russell , 2004). A cancerous growth then, 
by defmition, will develop through accumulation of such abnormal cells. 
1.2 Normal Breast and Breast Carcinoma 
1.2.1 Development of the Normal Female Mammary Gland 
The mammary gland, defmed as a modified form of the apocrine gland, is first 
recognizable, in the development of mammals and specifically humans, in the embryo at 
approximately 5 weeks gestation (Tavassoli, 1999). It first appears as an epidemlally-
dervied pair of bands referred to as ectodermal thickenings, milklines or milk ridges 
(Figure 3) (Thor & Osunkoya, 2008). These primitive milk ridges extend from the axilla 
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Milk 
ridge 
Figure 3 Earliest evidence of the presence of the mammary gland in the human 
embryo 
The presence of milk ridges within the embryo is first visible at approximately week 5 of 
gestation. These structures extend from the axilla to the groin area. (Brokaw, J.J.; 
Condon, K. ; Swantz, D.R., 2008) 
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1.2.1 Development of the Normal Female Mammary Gland (continued) 
down to the groin area (Tavassoli, Devilee, International Agency for Research on Cancer, 
& World Health Organization, 2003). Shortly after these have developed, the majority of 
these milk ridge atrophies and the remnant of such remains in the thorax region. By week 
7 of gestation, the remaining portion of the ridge proliferates and forms a primary mild 
bud that invades below the epidermjs, into the dermal layer, and at week 10 it begins to 
branch into solid epithelial structures. Such cellular structures become more defined by 
week 12 and are termed secondary milk buds. Between weeks 12 and 16 the areola and 
nipple will begin to emerge from the mesenchyme (Tavassoli, 1999). Throughout the 
remainder of the gestational period, the secondary milk buds will continue to lengthen 
and branch giving rise to the first emergence of lumens by week 20 (Revis, 2006). The 
lengthened secondary buds will eventually canalize and give rise to the lacteriferous 
ducts. 
At birth, the mammary gland is composed of 15-20 lobes which drain into the 
lactiferous ducts (Revis, 2006). Prior to the onset of puberty, the lobules do not contain 
any glandular structures; rather there exists only a few ducts. Before menarche, the ducts 
lengthen and become more defined as the terminal buds begin to materialize. 
Simultaneously, the amount of fat and connective tissue increases (Walker, 2000). 
Although mammary gland development begins embryonically, it continues into both the 
neonatal, where the gland is undeveloped, and pubertal stages and is considered complete 
postpartum in the adult female or during the childbearing years (Figure 4) (Revis, 2006; 
Watson & Khaled, 2008). 
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Figure 4 Mammary gland development between the stages of in utero to birth 
Early stages of the primary bud formation and secondary bud development (A and B, 
respectively). Emergence of ducts (C). Beginnings of nipple development (D). Further 
elongation and branching of the ducts and areola development (E). (Tavassoli, F.A. 1999) 
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1.2.2 Anatomy and Histology of the Adult Female Breast 
The adult female breast consists of 3 principal structures; the skin, 
subcutaneous tissue and the breast tissue which is divided into the parenchyma 
(functional unit of the breast) and the supportive tissue of the breast, known as the stroma. 
The breast tissue itself is comprised of 3 types of tissue, namely, glandular, fibrous and 
adipose tissue (Thor & Osunkoya, 2008). Young adolescent females generally have large 
amount of fibrous tissue and less adipose tissue, in contrast post-menopausal women 
usually have larger amounts of fatty breast tissue. The stratified squamous epithelium 
(thin, flattened cells arranged in layers) which overlies the skin, nipple and areola 
continues into the beginning of the ductal system, but then immediately changes to a 
double layered cuboidal epithelium (Lester, 2005). 
The breast, which rests on the pectoralis muscles of the upper chest wall, 
consists of 1 5-20 segments or lobes which are interconnected. The lobe is the functional 
portion of the breast and it is the site of milk production. Each lobe drains into the 
lactiferous and collecting ducts, which converge at the nipple (Figure 5). 
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Figure 5 Anatomy of the adult female breast 
The structure of the adult female breast. In humans, a pair of mammary glands are 
juxtaposed to the pectoralis muscle (2), which is adjacent to the upper chest wall 
and the ribs (1, 9). The site of milk production occurs within the Jobes (3), which 
drain into the Jactiferious ducts (6). This lobules are surrounded by fatty tissue (7). 
The nipple (4), which consists of fibrous tissue and smooth muscle, is surrounded 
by areola (5). The areola is more heavily pigmented than the surrounding skin (8). 
(Adapted from: Image: Breast anatomy normal scheme.png - Wikimedia Common ) 
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1.2.2. Anatomy and Histology of the Adult Female Breast (continued) 
The secretory units of the breast, the lobules, consist of a variable number of 
glands (acini). The interior of each acinus, those which are immediately adjacent to 
luminal side of the gland is lined with secretory epithelial cells. As such, they are the sites 
of milk production during latter part of pregnancy and post-partum. These luminal cells 
are surrounded by a flattened , discontinous layer of myoepithelial cells which have 
contractile ability. These two cell layers are then bounded by a basement membrane, a 
thin membranous layer of connective tissue (stroma) separating the duct from the rest of 
the lobular connective tissue (Watson & Khaled, 2008). Immediately, surrounding the 
acini is an area of gelatinous connective tissue, known as intralobular stroma, which is 
specific to the breast and responsive to hormones. (Figure 6) (Walker, 2000). 
Six to ten major ducts extend posteriorly from the nipple. Each of which diverge 
many times before terminating in the glandular structures, the lobules. Should a lesion 
occur within the ductal system, each ductal branch has been assigned a name to aid in the 
communication of the site of a lesion (Tavassoli, 1999). Within the lobule, the contents of 
each acini empties into an intralobular duct; the latter of which is the portion of the breast 
ductal system that is physically within the confines of the lobule and is named as such 
(Figure 6) (Elston & Ellis, 1998). The secretory epithelial cells of the acinus are those that 
have differentiated from the non-secretory cells of intralobular duct (Lester, 2005). This 
intralobular duct crosses through the lobular connective tissue and continues into what is 
known as the extralobular duct; together these two portions of the intricate duct system 
are referred to as terminal ducts (Figure 6, Figure 7, Figure 8A and 8B). 
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Figure 6 Illustration of the components within an adult female breast lobule 
The glands, or the acini, are the site of breast milk production. These acini are composed 
of two cell types. The secretory epithelial cells on the luminal side of the gland are 
surrounded by a layer of flattened myoepithelial cells which have contractile ability. 
These cell layer are surrounded by a thin layer of stromal connective tissue. (Walker, 
2000) 
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Figure 7 Illustration of the anatomical unit of the breast 
A portion of the breast stained with hematoxylin. The secretions from the lobules (Ll -L4) 
drain into the intralobular ducts and then into the extralobular terminal duct (ETD). The 
ETDs converge and its contents then spill into larger ducts (D), including the major duct 
and the lactiferous ducts. Ll together with it ETD make up the functional unit of the 
breast, the terminal ductal lobular unit (TDLU). (Adapted from 
tgmouse.compmed. ucdavis.edu/ .. ./an atom y3 .html) 
18 
A 
B 
~Duct , ..... ,,,,,,, 
Figure 8 Ductal system of the adult female mammary gland 
A is an illustration of the terminological breakdown of the adult female breast ductal 
system within a lobe (A) and a lobule (B). The contents of the acini or the terminal ducts 
of a lobule (DTL) filters into the intralobular terminal duct (lTD), these identities, 
including the intralobular stroma gives rise to a lobule (L). Within a single lobe, B, the 
sequential convergence of the ducts begins with the terminal (intra and then extra) ducts 
coming together to form the major ducts and merge to give rise to the lactiferous ducts. 
From there the lobule secretions are emptied into and stored in the lactiferous sinuses. 
(Adapted from IMAGES OF LECTURE: 1-16- srwimgl.htm and Tavassoli , 1999) 
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1.2.2. Anatomy and Histology of the Adult Female Breast (continued) 
In the adult breast, each lobule is associated with a single extralobular duct, which 
originates immediately outside the lobule (Figure 7, Figure 8A). The acini and its 
surrow1ding intralobular stroma, the intralobular ducts and the extralobular ducts 
constitute what has come to be known as the Terminal Ductal Lobular Unit (TDLU) 
(Figure 9) (Walker, 2000; Woolf, 1998). Each lobule is surrounded by a dense 
interlobular connective tissue, in contrast to the more loose intralobular stroma 
(Figure 1 0) (Tavassoli, 1999). 
The extralobular ducts that extend from each lobule converge and are known as 
the subsegmental duct or the major duct. The secretions from all glands within each lobe 
come through the major ducts and into the lactiferous ducts. The milk is then stored in the 
lactiferous sinus; a dilated portion of the lactiferous duct (Figure 8B) (Tavassoli, 1999). 
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Figure 9 Hematoxylin and Eosin stain of a section containing a terminal duct 
lobular unit (TDLU) 
A H&E stain of a portion of normal adult female breast. Note the dense interlobular 
stroma (ELS) that surrounds the lobules which contain glands/acini that are embedded in 
the loose intralobular stroma (ILS). The acini, intralobular stroma, intralobular terminal 
ducts (lTD) and the extralobular terminal ducts (ETD) make up the functional unit of the 
breast the TDLU. (Adapted from Thor, 2008) 
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Figure 10 Intralobular stroma verses the interlobular stroma within the normal 
adult female mammary gland 
A H&E stained section of normal breast tissue illustrating the interJobular stroma, which 
is a dense network of connective ti ssue and is intermingled with adipose ti ssue (fat) . In 
contrast, the intralobular stroma is a loose network of connective tissue. (40X 
magnification) (Adapted from Tavassoli, F.A. 1999) 
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1.2.3 Hormonal Regulation in the Development of the Adult Female Breast 
A coordinated hormonal (systemic and local) action, is required for female 
mammary gland development. Hormones have either a passive or active role in its 
development. Specific hormones influence the development of specific portions of the 
breast; prolactin, and two steroid hormones, namely, estrogen and progesterone are 3 such 
hormones (LaMarca & Rosen, 2008). While estrogen primarily contributes to the growth 
and development of the ducts, progesterone influences the growth and development of the 
lobular units (McManus & Welsch, 1984; Tavassoli, 1999). The function of both estrogen 
and progesterone are dependent upon the presence of prolactin; a hormone that is released 
from the pituitary gland. Estrogen stimulates the epithelial cells to divide, but this will 
only proceed if prolactin, insulin and other growth hormones are present. All of these 
hormones exploit their actions throughout all stages of man1mary gland development 
from the embryonic stage to neonatal development, puberty and into the reproductive 
years of an adult female (Harris, 2000; Reyniak, 1979; Tavassoli, 1999). With the 
commencement of menstruation, both the TDLUs and the epithelial cells will continue to 
develop and differentiate, respectively. The mammary glands will continue to respond to 
a cyclic hormonal environment that corresponds with menses (Thor & Osunkoya, 2008). 
1.2.4 Diagnosis of Breast Abnormalities and Invasive Beast Carcinomas 
There are several different anomalies of the female breast. Some are classified 
as normal physiological changes and are not associated with an increased risk for 
development of breast carcinoma. Many clinicopathological criteria have been established 
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to aid in distinguishing these nonnal physiological changes from more precarious 
pathological conditions, both benign and malignant. 
Most breast conditions are identified through routine mammograms in women 
who are asymptomatic; women less frequently present with symptoms such as pain, skin 
changes, nipple discharge, palpable mass or lumpiness (Lester, 2005). Pain is the most 
common symptom, however a low percentage of these cases prevail as a result of breast 
carcinoma. Majority of such masses are associated with either menses or they are simply 
random and non-cyclical and can be managed using hormonal therapy. Causes of pain can 
include trauma, infection or a ruptured cyst (Barton, Elmore, & Fletcher, 1999; Lester, 
2005). The second most common breast condition symptom, a palpable mass, may be 
associated with normal cyclical changes of the breast or it can be a neoplastic lesion; this 
warrants further investigation to distinguish between the two. As a result of decreased 
honnone levels with increasing age, the breasts' stromal tissue becomes more dense and 
there is a thickening of the basement membrane surrounding the glandular structures. 
This can occur within the lobules at an uneven rate and produce palpable lumps (Walker, 
2000). 
Characteristic features of breast lumps are used, in combination with other 
investigative methods, to help distinguish between those which are benign from those 
which are carcinomas. These include the circumscription of the mass (well- or poorly-
defined), the number of masses, the density (soft or dense), and the mobility of the mass 
(mobile or fixed) (Walker, 2000). 
Diagnostic investigations used to examine breast lesions may include 
mammography, magnetic resonance imaging (MRI), ultrasound, fine-needle aspiration, 
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biopsy and or frozen sections of samples obtained during surgery. Mammography and 
breast MRI are used both as a screening tool (usually performed annually or once every 
two years) and to further characterize palpable masses. 
Screening mammographies were introduced in 1980 with the goal of detecting 
early, carcinomas that are non-palpable in asymptomatic individuals. Women who are 
asymptomatic are encouraged to have an annual screening mammogram once they reach 
the age of 40. However, screening mammograms can also be requested for women who 
are less than 40 years but are at risk for developing breast cancer. Many institutions also 
use breast MRI as part of their standard care for individuals who are at increased risk for 
developing breast cancer. Leach (2009), reported that there is a substantial amount of 
evidence which supports the recommendation to use breast MRJ when screening 
individuals who are at increased risk for developing breast cancer. In his comparative 
study review, Leach (2009) stated that several studies report that MRI has twice the 
sensitivity of x-ray manunography for screening women who are at increased risk. 
Individuals who are carriers ofBRACI or breast cancer 2 (BRAC2) mutations or those 
who have E-cadherin mutations are at an increased risk for developing breast cancer. 
Mutations in the gene coding for the cell-cell adhesion protein, E-cadherin, has been 
linked to the development of breast carcinoma by increasing cell proliferation, invasion 
and/or metastasis (Berx, Becker, Hofler, & van Roy, 1998). A woman presenting with a 
palpable mass is usually first sent to have a diagnostic mammogram and an ultrasound so 
that the location, size, and number of masses can be recorded. A diagnostic mammogram 
cannot distinguish between lesions that are cystic from those that are solid, but an 
ultrasound can which is why both are used in the investigation. Other details that maybe 
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identified from a mammogram are the mass density and presence or absence of 
calcifications. Most tumors are solid and will show up as a dense body on radiographs. 
They can also be detected through a manunogram long before they become clinically 
palpable (Walker, 2000). The deposition of calcium salts, calcification, is often associated 
with secretory or necrotic material (morphological characteristics associated with cell 
death). 
There are two types of calcification, macro and micro. Macro is a large 
collection of calcium deposits and not usually associated with breast carcinoma, in 
contrast, microcalcifications are non-clustered trace amounts of calcium and is often 
found in association with DCIS or invasive breast carcinoma. 
Following a mammogram the radiologists reads the image and writes a report 
detailing the image and describing his/her medical opinion on what should be done next 
in regards to treatment and follow-up. The American College of Radiologists devised a 
set of standards for assessing mammograms, which are collectively known as Breast 
Imaging Reporting and Data System (BIRADS) (Eberl, Fox, Edge, Carter & Mahoney, 
2006). Within BIRADS framework there are 7 categories, 0-6, with categories 3-6 
requiring some form of follow-up. The absence or presence of calcifications are noted in 
the report and, if present, are analyzed based on the size, shape, number and distribution. 
More specifically, calcifications that are large, round or oval in shape and uniform in size 
are more likely to be associated with benign lesions. However, calcifications that are 
heterogenous in size, polymorphic and/or branching have a higher probability of being 
associated with malignant lesions. Assessment of calcifications are included in the 
BIRADS framework and are classified into 3 groups; those which are benign (1 ), those of 
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intermediate concern (2) and those that are more likely to be associated with a malignant 
tumor (Eberl et al., 2006). 
The particulars noted in the results of a mammogram and/or an ultrasound are 
used by clinicians to determine the next course of action; which may be a follow-up 
mammogran1, a needle-core biopsy or fine-needle aspiration (Miltenburg & Speights, 
2008). 
Fine-needle aspiration biopsy (FNAB) is a technique whereby a thin needle is 
inserted into the suspicious area, using ultrasound or man1mography as a guide for non-
palpable lesions, cells are extracted, smeared onto a glass slide, stained and then 
examined by a pathologist. It is considered to be a minimally invasive procedure that is 
relatively painless and can be carried out without the need for general anesthetic. FNAB 
is a less traumatic event than the larger, tissue biopsy procedure and samples can be 
processed relatively quick. The concern is which is often regarded as a disadvantage, that 
the cells from the suspicious area will be missed and therefore give a false-negative 
result. Another disadvantage is that FNAB cannot always distinguish between invasive 
lesions from those which are not invasive. For this reason, FNAB should only be 
performed by experts in cytopathology. Studies looking into the use ofFNAB for breast 
lesions have shown that the accuracy of reading FNAB results improve with experience 
and should be used only in combination with core needle biopsies (Feoli, Paesmans, & 
Van Eeckhout, 2008; Nggada et al., 2007). 
Core needle biopsy (CNB) involves the removal of approximately 6-8 cores of 
tissue from the lesion using a needle that is inserted percutaneously. A for FNAB, this 
technique can be carried out in using image-guidance for non-palpable masses. This 
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procedure is considered to be more advantageous than FNAB because it is usually more 
accurate and it can remove a large enough sample that contains surrounding tissue which 
can be compared to the morphology of the lesion. It is also more absolute than FNAB in 
identifying lesions which are borderline and it can allow for the distinction between IDC 
and ILC to be made; all of which are particularly important in regards to the devise of a 
treatment plan (Houssami, Cuzick, & Dixon, 2006; Oyama, Koibuchi, & McKee, 2004). 
The disadvantages include the need for anesthetic, overnight processing and since it 
removes only a small sample ofthe lesion it can miss morphological features indicative of 
a more serious disease (Walker, 2000). 
On occasion, some masses are highly suspicious but cannot be confirmed 
though radiographical or biopsy measures. In these situations lesions are diagnosed 
intraoperatively using frozen sections. For this, samples of the lesion and surrounding 
tissue are snap frozen, sectioned, cut and stained and microscopically evaluated by 
pathologists within a relatively short period of time (Walker, 2000). However, this 
procedure is not routinely carried out as a number of cases diagnosed through this method 
have been identified as false-positives. In addition, this procedure may disadvantageous 
for the patient since before surgery they are unaware of the extent of surgery. Ideally, the 
mass is removed through a relatively simple procedure called a lumpectomy. However in 
some cases the mass is large or there are multiple lesions, both of which may require a 
mastectomy. Therefore, before a patient goes in for surgery she may not know if a 
lumpectomy or a mastectomy will be performed. In most cases, core biopsy (not FNAB) 
is done for suspicious lesions, followed by lumpectomy and axillary lymph node 
dissection. Alternatively, the patient could have a modified radical mastectomy. 
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1.2.5 Pathological Characteristics of Benign and Malignant Breast Conditions 
All non-infiltrating breast lesions are pathologically categorized into 1 of the 4 
following groups (Table 1) (Croce, Bretz-Grenier, & Mathelin, 2008; Lester, 2005; 
Walker, 2000): 
1. Non-proliferative breast changes 
2. Proliferative without atypia 
3. Proliferative disease with atypia 
4. Carcinoma in situ 
1.2.5.1 Non-proliferative Breast Changes 
This group of breast changes is often referred to as fibrocystic change, but 
Lester et. al. (2005) classified them as non-proliferative since they are conditions for 
which there is not an increased risk for future development of breast carcinoma. Many of 
these non-proliferative breast changes can arise clinically due to the presence of a 
palpable lump or areas of calcification that show up during a routine mammogram. 
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Table 1 Pathologic Lesions and Relative Risk for Breast Cancer Development1,2 
Pathologic Lesion Relative Risk Breast at Risk 
Non-proliferative 1.0 Neither 
Breast changes 
Duct ectasia 
Cysts 
Apocrine change 
Mild Hyperplasia 
Adenosis 
Fibroadenoma without complex features 
Proliferative Disease 
without Atypia 1.5-2.0 Both breasts 
Moderate or florid hyperplasia 
Sclerosing adenosis 
Papilloma 
Complex sclerosing lesion (radial scar) 
Fibroadenoma with complex features 
Proliferative Disease 
with Atypia 4.0-5.0 Both breasts 
Atypical ductal hyperplasia 
Atypical lobular hyperplasia 
Carcinoma in Situ 8.0-10.0 
Lobular Carcinoma in Situ Both breasts 
Ductal Carcinoma in Situ Ipsilateral breast 
1 Adapted from Lester, S.C., 2005 
2 Relative Risk values are appropriate for patients without a family history of breast 
cancer 
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1.2.5.1 Non-proliferative Breast Changes (continued) 
When patients manifest such clinical observations it warrants further 
investigation to be certain that the change is indeed non-threatening. Some ofthe 
conditions included in this group are duct ectasia, cysts, apocrine change, adenosis, 
fibroadenomas and hyperplasia. There are different grades of hyperplasia; mild, moderate 
and florid (severe). The latter two types of hyperplasia are those which confer a 1.5-2.0 
fold increase in developing breast carcinoma (Lester, 2005 ; Rosai & Ackerman, 2004; 
Thor & Osunkoya, 2008; Walker, 2000). However, mild hyperplasia is not associated 
with an increased risk for developing breast carcinoma. Please refer below for a 
description of hyperplasia, for all other conditions please refer to appendix A. 
As previously mentioned, normal breast acini consist of a single layer of 
luminal epithelial cells which are surrounded by a layer of myoepithelial cells. Epithelial 
hyperplasia is when there are more than 2 cell layers; more specifically there is an 
increase in the proliferation of the epithelial cell layer. An increased cellular proliferation 
that may occur as a result of a shift in the balance of between apoptosis and cell 
proliferation in favor of the latter (Bai et al., 2001 ). An example of normal hyperplastic 
growth would be the increase in the number of glandular cells during pregnancy. 
Although hyperplastic cells can give rise to a grossly enlarged lesion, a result of a 
response to specific stimuli, in many cases they still have a physiological response to 
normal cell control mechanisms (Lester, 2005; Rosen, 2001 ). It is considered mild 
hyperplasia when there are less than 4 cell layers, this can affect the whole duct or just a 
segment of a duct. This increase in the epithelial layer can be evenly distributed around 
the duct or can slightly project into the lumen of the duct and give rise to what is known 
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as papillary structures. Moderate hyperplasia is characterized by 5 or more cell layers 
and can have papillary structures that will either extend into the lumen or may occupy the 
entire lumen. Florid hyperplasia is easily distinguishable from moderate hyperplasia 
since the ducts are significantly increased in size compared to non-hyperplastic ducts and 
the proliferative epithelium often fills the ducts (Lester, 2005; Rosai & Ackerman, 2004; 
Thor & Osunkoya, 2008; Walker, 2000). A previous study had also found a link between 
the expression ratio of two isoforms (a and~) of Estrogen Receptor (ER), hyperplasia and 
risk for subsequent development of breast cancer. It was found that ER~ expressed at a 
lower level compared to ERa, hence a high ERa:ER~ ratio, is associated with 
hyperplastic cases that are likely to develop breast carcinoma (Shaaban et al. , 2005). 
1.2.5.2 Proliferative Disease without Atypia 
These group of proliferative breast diseases often do not present as palpable 
lumps but rather they are often detected during routine mammograms or biopies that were 
ordered by physicians for other reasons. Diseases which are categorized under this group 
include moderate and florid hyperplasia, sclerosing adenosis, papillomas, complex 
sclerosing lesions and fibroadenomas with complex features. For all of these changes, the 
increased the risk for developing breast carcinoma is 1.5-2.0 fold (Lester, 2005). A more 
detailed description for each of these conditions can be found in Appendix A. 
1.2.5.3 Proliferative disease with atypia 
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) 
often resembles DCIS and LCIS, respectively, but lack certain features. In ADH the 
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number of lesions per specimen fall short of that observed for DCIS and the cells do not 
completely fill the duct. Peripheral cells of an ADH lesion are columnar and the nuclei of 
cells that are more central to the lesion are more rounded. Since the cells of ADH do not 
completely fill the duct, rounded spaces may be noted throughout the lesion. ALH 
involves at least half of the acini with the cells demonstrating little variation in their size 
or their shape. ALH holds a more aggressive phenotype when it advances into the ducts 
and is therefore associated with a higher risk for future breast cancer development (Page, 
Dupont, & Rogers, 1988). The risk for carcinoma is 4-5 times higher; which increases to 
10 times if the patient has a first degree relative that has had breast cancer (Table 1) 
(Page, Dupont, Rogers, & Rados, 1985). 
1.2.5.4 Ductal Carcinoma In Situ and Lobular Carcinoma In Situ 
The TDLU, previously described, is the site where most of the non-
proliferative breast changes and proliferative breast diseases arise. However, it is 
typically within the larger ducts that most papillomas and papillary carcinomas manifest. 
Breast carcinomas are divided into two main categories, those that are non-invasive and 
those that are invasive. 
Non-invasive breast carcinoma is used to describe neoplasms which are 
confined to the duct or lobule and has not advanced beyond the confines of the basement 
membrane; as such it does not have the potential to metastasize to other sites. Two main 
groups of in situ breast cancers are Ductal Carcinoma In Situ (DCIS) and Lobular 
Carcinoma In Situ. 
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DCIS, also referred to as intraductal carcinoma, is a population of cells that, 
individually, appear morphologically similar to cells of invasive carcinomas. These 
abnormal cells cumulate within the ducts and although the basement membrane and the 
myoepithelial cell layer is in tact, the number of cells that comprise the latter may have 
lessened. However, disruption of both the basement membrane and the myoepithelial 
cells layer are a pre-requisite for progression to an invasive carcinoma (Shekhar, Tait, 
Pauley, Wu, Santner, & Nangia-Makker, 2008) 
There are several different histological subtypes of DCIS and often a 
pathologist may notice several types within a single specimen. These different types 
include solid, cribriform, comedocarcinoma, papillary and micropapillary 
(Lester, 2005). Solid DCIS is used to describe lesions in which the duct is completely 
filled with neoplastic cells (Figure 11 ). In contrast, papillary (Figure 11) and 
micropapillary DCIS have fibrovascular cores and cancerous papillae that project into the 
lumen, respectively. The micropapillae have another histological distinguishing feature, 
in that, the base through which the projections are attached to the duct wall is constricted. 
Cribriform DCIS has rounded spaces that exist between the cancer cells which are usually 
filled with calcified secretions (Figure 11) (Figurel2) (Burstein, Polyak, Wong, Lester, & 
Kaelin, 2004). Comedocarcinoma is a type ofDCIS that is characterized by ducts 
completely filled with cells that contain a central necrotic area having calcified material 
within it; it is this feature that is often detected on mammogran1s (Fisher et al., 1999). The 
necrotic debris build-up arises due to both apoptosis and passive cell death or oncosis 
(Moinfar, Mannion, Man, & Tavassoli, 2000). Comedocarcinoma is considered to be a 
more aggressive (faster growing) form ofDCIS, with approximately 40% progressing to 
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an invasive carcinoma. Pathologists are often very cautious when reviewing cases of 
comedocarcinomas, as there have been reported cases of invasive ductal carcinomas 
resembling comedocarcinoma with the presence of nectrotic debris. This is an issue that is 
usually resolved and confirmed using routine laboratory immunohistochemical staining 
(Pervez & Khan, 2007). 
Usually DCIS does not form a palpable lun1p and is habitually detected through 
man1mography. Even though the cancer is contained, the relative risk of an in situ 
recurrence and subsequent development of breast carcinoma following treatment for 
DCIS is substantially higher (Thor & Osunkoya, 2008). The risk of future development of 
invasive carcinoma is about 10 times that of a person who has never had breast 
carcinoma, but this is largely influenced by the course of treatment. Due to this high risk, 
women are referred for appropriate treatment and should be followed by a screening 
program (Sanders, Schuyler, Dupont, & Page, 2005). 
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Figure 11 An illustration of the histological appearances of 3 types of DCIS 
lllustration of three different types of DCIS. In solid DCIS, the ducts are fiJJed with 
carcinogenic cells that are surrounded by a basement membrane (A). Cribriform DCIS is 
characterized by cancer ceJJs which do not completely fiJJ the lumen of duct and 
spaces/pockets which exist in between the cancer cells (B). In papillary carcinoma, the 
cancer grows into the lumen as "finger-like" projections (C). The malignant celJs and 
basement membrane and lumen of the duct are marked by an A, B and C, respectively. 
(Adapted from www.breastcancer.org) 
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Figure 12 
Cribrifom1 
Basement 
membrane 
Comedo 
Necrosis 
Basement 
membrane 
Comedo 
Cribriform DCIS, Comedo DCIS, Comedo DCIS with early infiltrate 
H & E staining of two common forms of DCIS, Cribriform and Comedo. Crjbriform has 
pockets of spaces between the cancer cells (A), whereas Comedo has a central area of 
necrosis (B and C). In each of A and B the cancer is contained within the basement 
membrane, however inC, there is evidence of early jnfi ltrate (arrow) in the presence of 
comedo DCIS. (Magnification lOOX) (Burstein, 2004) 
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1.2.5.4 Ductal Carcinoma In Situ and Lobular Carcinoma In Situ (continued) 
In Situ carcinomas are assigned a grade of I, II or III by a pathologist to reflect 
the morphology of the carcinoma in relation to normal breast tissue. A grade of I through 
to III is assigned based on how closely they resemble the normal cells. How well the 
neoplastic cells resemble the normal is defined by parameters such as the tubule 
formation, mitotic count, and the nuclear pleomorphism. Also an important consideration 
when assigning a grade to an in situ lesion is the extent of central necrosis (S ilverstein et 
al., 1996; Wells, Carney, Eliassen, Grove, & Tosteson, 2000). Grade I (well-
differentiated) lesions are those which closely resemble the normal cells and are often 
slow-growing, whereas grade II (moderately differentiated) lesions are those which do not 
resemble the normal cells and appear to be growing faster than that of normal cells. Grade 
TTl (poorly differentiated) are those cells which are faster-growing and morphologically 
have no resemblance to normal cells. For example, those that are low grade (well-
differentiated) would demonstrate well-defined tubule formation, low mitotic count and 
small uniform cells. DCIS can arise in several areas of the ductal system (multi focal) and 
this is often found to be associated with grade I type ofDCIS lesions (Foschini et al. , 
2007). The grade ofDCIS can influence the type and the aggressiveness ofthe treatment 
plan, however the validity of its application has been challenged (Boland, Chan, Knox, 
Roberts, & Bundred, 2003; MacAusland et al., 2007; Silverstein et al., 1996). In one 
study, it was found that for the low grade DCIS group, it took decades before an invasive 
phenotype developed when not treated by surgical means (Sanders et al., 2005). 
DCIS is 4 times more common than LCIS, which is a form of in situ cancer that 
develops in the lobules, more specifically within the acini of the lobules. LCIS is thought 
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to incm a higher risk of a recunence or developing invasive breast carcinoma in the 
future; a risk that is about 8-1 0 times that of someone who has never had breast cancer 
(Chuba et al. , 2005). The risk for developing infiltrating breast carcinoma is higher for the 
ipsilateral breast, which is independent of the amount ofLCIS that was present initially 
(Li, Malone, Saltzman, & Daling, 2006). If an invasive cancer does develop in the future 
it can be lobular or ductal. It is an uncommon breast abnormality and it is not usually 
detected through mammograms but rather biopsies of the breast performed for other 
reasons. LCIS histology appears as cells which are loosely cohesive and completely 
filling the acini. However, the overall outline of the lobule is still apparent. 
E-cadherin is a transmembrane protein involved in calcium-dependent cell-to-
cell adhesion. Since there is loss of E-cadherin in LCIS, but not DCIS, staining of paraffin 
sections with E-caherin can aid in the distinction between the two (Stein, Zisman, 
Rapelyea, Schwartz, Abell & Brem, 2005) . 
Treatment for DCIS and LCIS typically involves surgery combined with some 
adjuvant therapy. The extent of the smgery can be either breast conserving (lumpectomy), 
or breast removing surgery (mastectomy), which largely depends on the size, number and 
grade of the lesion(s). When lesions are removed, the margins are painted with an ink so 
that when it is processed and sectioned the margin of excision of the removed tissue can 
be identified. The pathologists will note the distance between the cancer cells and the 
edge of the removed tissue. This aids in determining a treatment plan. For example, if the 
cancer cells are close to the edge additional smgery may be warranted. If the lesion is 
confined to one area and can be removed with clear margins of resection, the 
recommended form of treatment is lumpectomy followed by radiation. Radiation 
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following lumpectomy has been shown to significantly reduce ipsilateral recurrence of 
breast carcinoma in those patients. As well, administration of another adjuvant therapy, 
Tamoxifen, has been shown to inhibit increased breast cell proliferation and reduce the 
recurrence of breast cancer in ER positive cases (Cunnick & Mokbel, 2004; Mokbel, 
2005). Hence, Tamoxifen is often factored into the treatment plan for breast cancer 
patients. Fisher et al. (1999) demonstrated that if Tamoxifen is added to the treatment 
regime there is a reduction in the breast cancer events by year 5 from 13.4% to 8.2% 
(P=0.0009). If there is more than one lesion and they are located in different regions of 
the breast and if the grade of the lesion is high then a mastectomy may be proposed. 
1.2.5.5 Invasive Lobular and Ductal Carcinomas 
Invasive breast cancer indicates that it has spread beyond the milk duct(s) or 
acini. In that, the cancerous cells has broken through the basement membrane and 
invaded the surrow1ding normal tissues via the vascular or lymphatic system. Of all the 
invasive breast cancers, about 80% are ductal carcinomas and approximately 5% are 
lobular carcinomas, with the remaining cases being special or rare forms of breast 
carcinoma. Most women diagnosed with breast cancer who have not been screened 
through mammography, present with a palpable mass. Unfortunately, the majority of 
these cancers have already metastasized to the axillary (armpit region) lymph nodes 
(Lester, 2005). 
While it is still unclear as to how an invasive breast lesion develops from an in 
situ carcinoma, many theories have been proposed. lt has also been difficult to identify 
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which gene(s) are specifically involved in the invasion step (Porter et al. 2005). 
However, it has been proposed that 7 changes must occur in normal cells to become 
hyperplastic and give rise to an in situ carcinoma and invasive breast carcinoma (Figure 
13) (Lester, 2005). Early in the process, there needs to be an increase in genomic 
instability and/or loss of both growth inhibition and apoptosis. In the case of hereditary 
breast cancers, these changes may occur because of mutation in genes involved Ln those 
particular pathways. In addition, the cell must gain the ability to supply its own growth 
signals ("self-sufficient growth") and they must be capable of initiating vascularity which 
will provide a route for nutrients and other growth promoting molecules. As well , the 
cells must continue to proceed through the cell cycle without interruption. Several 
theories have been suggested as to how cancer cells can invade through the basement 
membrane, myoepithelial cell layer and into the stroma. It is proposed that the 
myoepithelial cells and stroma undergo changes as opposed to the malignant cells 
acquiring the ability to invade these layers (Lester, 2005). In contrast, Tait et al. (2007) 
has proposed that it is the malignant cells which recruit or initiate the development of a 
stroma that permits its invasion. 
Histologically, invasive ductal carcinoma varies from those that form well-
defined tubuJes that have monomorphic cells to those that have sheet of cells, with no 
evidence of tubules, with variation in size and shape (Figure 14). The neoplastic cells are 
also notably larger than those of normal epitheliun1. In the case of lobular carcinoma, the 
cells tend to be small in comparison to that of invasive ductal carcinoma and infiltrate as a 
single file of cells or ill a targetoid pattern (Figure 15). 
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Pathobiologic events that are associated with the progression 
from normal to breast carcinoma 
H&E stained breast tissue sections indicating the progressional steps in going from a 
normal cell to non-infiltrating lesions such as hyperplasia or DCIS to invasive ductal 
carcinoma. Genetic changes occur in genes that regulate cell proliferation and 
apoptosis, such that cells can evade control of the normal cell growth and 
proliferation. In some cases, an individual may inherit a mutation, germJine 
mutation, in such critical genes putting them at high risk for developing breast 
carcinoma. As a lesion becomes more invasive, it will develop a blood supply which 
serves a dual role. One it will allow the tumor to receive nutrient and other growth 
factors so that it can continue to grow and it serves as a mode for which the cancer 
cells can travel to other organs. (Adapted from Burstein, 2004) 
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A: Well-Differentiated B: Poorly Differentiated 
Figure 14 Histological differences in grade of invasive ductal carcinoma 
Some invasive ductal carcinomas have well-defined tubules formed from cells that are of 
the same size and similar shape (A: Well-differentiated) . However, many invasive 
carcinomas do not have any tubules, but rather a network of cells of varying size and 
shape (B: Poorly-differentiated). (H&E stain) (Adapted from Tavassoli, F.A. , 1999) 
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A: Targetoid pattern 
Figure 15 H&E stained sections of two areas of lobular carcinoma 
with different morphologies 
Lobular carcinoma can have many morphological pattern . The most common 
een are those which fo rm solid pockets of cells with a targetoid pattern, where 
cells appear to wrap them selves about one nest of celJs (A). Another common 
pattern is when the cells infil trate in a single fi le (B). 
(adapted from www.med-ed. virginia.edu/courses/path/gyn/breast6.cfm) 
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1.2.5.5 Invasive Lobular and Ductal Carcinomas (continued) 
Some ofthe hormonal risk factors are directly related to an increase in 
exposure time to the steroid hormone estrogen; these include early menarche, late 
menopause, nulliparity (a women who has never given birth) and women taking hormone 
replacement medications to treat menopausal symptoms. A risk factor that is related to 
amount of estrogen in the body, is obesity; a risk that also correlates with poor prognosis 
(Carmichael, 2006). In obese patients the amount of estrogen is often higher than non-
obese patients; a risk factor that also puts them at an increased risk for endometrial 
cancer. 
Whether invasive ductal and lobular carcinomas differ in regards to prognosis 
and biology has been a controversial issue for some time. Some believe that lobular 
carcinoma is associated with a prognosis that is similar to that of ductal carcinoma (Viale 
et al., 2008). Pestaozzi, et al. (2008) compared and contrasted the prognosis and biology 
ofiDC and ILC in 12, 206 breast cancer patients. The results of this study demonstrate 
that the 6111 year mark, following the diagnosis of lobular carcinoma, is associated with a 
better prognosis in comparison to ductal carcinoma. However, at the 1 01h year the 
prognosis is worse for ILC than that for ductal carcinoma. 
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1.2.6 Malignant Conditions of the Adult Female Breast: Stage and Grade 
Staging is a procedure that is not only used to predict a patient's survival and 
treatment plan, it also a universal system that permits clinicians worldwide to 
communicate about the disease. Using infom1ation gathered from radiographs, surgery 
and pathological investigations of the tumor tissue, clinicians classify each breast tumor 
into 1 of the 4 possible stages. Each of these stages is associated with a similar outcome; 
tumors that are stage I, for example, have approximately the same prognosis. The size of 
the primary tumor (T), the number regional lymph nodes involved (N) and the presence 
or absence of distant metastases (M) are the 3 determinants used in the classification 
(TNM classification) of breast cancer staging (Sobin & Wittekinde 1997). In other words, 
the assessment will reveal if the cancer has spread to other areas of the body, number of 
lymph nodes and if so, where and how many, as well as the primary tumor size. See Table 
2 for further dissection of the TNM classification. Together, the scores forT, N, and M 
are used to determine which stage the cancer is in for each patient. Stage 0 is used to 
describe those tumors that are non-invasive such as DCIS or LCIS. There is no evidence 
that the tumor has left the site in which it has occurred and is not present in another area 
of the body that was assessed. Stage I is when the tumor is 2cm or less in greatest 
dimension, there is no lymph node involvement and no metastases. Stage II is divided 
into 2 subcategories, stage IIA and stage liB. Stage IIA has 3 possibilities which include, 
those in which no tumor is found in the breast but cancer is present in the ipsilateral 
(same side) axillary lymph nodes, tumor is 2cm or less and is also present in the axillary 
lymph nodes or the tumor is between 2 and 5cm and there is no cancer in the axillary 
lymph nodes. If a tumor is between 2 and 5cm in diameter and involves the axillary 
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lymph nodes then it is stage liB. However, a tumor can also be stage liB if it is larger 
than Scm in dian1eter but it has not spread to the axillary lymph nodes. Stage IliA 
characterizes tumors that are not in the breast tissue but rather are detected in the axillary 
lymph nodes which are clumped together or are adhered to other structures. Another 
group of tumors that are also classified as stage IliA are those that have a diameter of 
either Scm or less or those which are greater than Scm and are associated with spread to 
axillary lymph nodes that are clumped together or attached to other structures. A tumor of 
any size with spread into the chest wall and/or the skin of the breast, with or without 
spread to lymph nodes that have clumped together or attached to other structures, is 
classified as stage IIIB. In Stage IIIC, the tumor may be of any size, there is spread to the 
chest wall and /or skin and the cancer has also metastasized to lymph nodes above and 
below the collar bone. Metastases at presentation, or Stage IV, means that the cancer has 
advanced beyond the breast and regional lymph nodes and is now present in other organs 
such as the lungs, liver, bone or brain. Also taken into consideration when staging a breast 
tumor(s) is the presence or absence of ER, PR and Her2/neu. Her-2/neu is a proto-
oncogene that codes for a receptor protein involved in signal transduction pathways that 
give rise to cell growth and differentiation. Her-2/neu is amplified in about 1 0-20% of 
breast cancers and can lead to an increase in the amount of Her-2/neu protein. An increase 
in this protein receptor is often associated with increased breast disease recurrence and 
poor prognosis (Moelans, de Weger, Ezendan1 & van Diest, 2009). 
48 
Table 2 TNM Classification used for Breast Cancer Staging' 
Code 
Tumor Size2 
TX 
TO 
Tis 
Tl 
T2 
T3 
T4 
Regional Lymph Node3 
NX 
NO 
Nl 
N2 
N3 
Distant Metastases 
MX 
MO 
Ml 
Description 
Primary tumor cannot be assessed 
No evidence of primary tumor 
Carcinoma in situ 
Tumor is 2cm or less in greatest dimension 
Tumor is more than 2cm but not more than Scm in 
greatest dimension 
Tumor is greater than Scm in greatest dimension 
Tumor of any size with extension to the chest wall or skin 
Regional lymph nodes cannot be assessed 
No metastases to regional lymph nodes 
Metastases in movable ipsilateral axillary lymph nodes 
Metastases in fixed ipsilateral axillary lymph node(s) 
Metastases to internal mammary lymph nodes 
Presence of distant metastases cannot be assessed 
No distant metastases 
Distant metastases 
1 Adapted from the "December 2004 Revision, TNM 6th Edition: Disease Staging Form" 
utilized by the Cancer Care Program within the Or. H. Bliss Murphy Cancer Centre, 
St. John' s, NL. 
2 Tumor size Tl is further classified into Tmic, Tla, Tlb, Tlc to represent tumor sizes 
between 0.1 em (microinvasion) to 2cm 
3 Regional Lymph Node N2 and N3 is furthur classified into N2a, N2b and N3a, N3b, 
N3c 
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Table 2 continued TNM Classification used for Breast Cancer Staging1 
Stage grouping 
Stage 0 Tis NO MO 
Stage 1 T l NO MO 
Stage IIA TO Nl MO 
Tl Nl MO 
T2 NO MO 
Stage liB T2 N1 MO 
T3 NO MO 
Stage IliA TO N2 MO 
Tl N2 MO 
T2 N2 MO 
T3 Nl ,N2 MO 
Stage IIIB T4 NO, Nl , N2 MO 
anyT N3 MO 
Stage IV anyT anyN Ml 
1 Adapted from the "December 2004 Revision, TNM 6th Edition: Disease Staging Form" 
utilized by the Cancer Care Program within the Dr. H. Bliss Murphy Cancer Centre, 
St. John' s, NL. 
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1.2.6 Malignant Conditions of the Adult Female Breast: Stage and Grade 
(continuetl) 
Histological grade is also a strong predictor of survival for breast cancer 
patients and some researchers believe it should be included in the staging system (Rakha 
et al., 2008). In 1950, H.J.G.Bloom proposed a means of assessing the grade of a tumor 
that was to be based on 3 factors: (1) extent of tubule formation, (2) nuclear 
pleomorphism, (3) nuclear hyperchromasia and mitotic activity (Bloom, 1950; Tavassoli, 
1999). Since this time, the grading system has been modified many times and as such has 
evolved into one that is currently more appropriate. This modified version is referred to as 
the Modified-Bloom-Richardson Grading System. Currently, it is a system whereby a 
score of 1 to 3 is assigned for each of the above factors and the total of these 3 scores 
(ranging from 3-9) is used to categorize the tumor as low, moderate or high grade. A total 
score of 3-5 is a low grade, well-differentiated tumor, 6-7 is a moderately differentiated 
tumor and a score of8-9 is a high grade breast tumor. Ofthese, it is the high grade tumors 
that are associated with a worse prognosis. 
The following criteria are used in the compilation of the score: 
Tubule formation: 
Tubules that are well defined (present in greater than 75% of the lesion) get a score of 1 
and those with little, those that have a moderate degree of tubule formation (1 0-75% of 
the lesion) are given a score of 2 and those with no evidence of tubule formation (less 
than 10% of the lesion) receives a score of 3. 
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Nuclear Pleomorphism: 
Breast cancer specimens with very little nuclear pleomorphism are assigned a score of 1 
and those that have a moderate variation in nuclear size and shape get a score of 2. Tumor 
in which the cells are extensively pleomorphic are given a score of 3. 
Mitotic Activity 
The number of mitotic figures, that are located in the periphery of the tumor or in the 
highest mitotically active area of the lesion, in 10 high power fields are counted to 
determine the mitotically activity (Tavassoli, 1999). Tumor specimens that have few or 
absent mitotic activity get a score of 1 and those with a lot of mitotic activity are assigned 
a score of3. 
It has been determined that if one were to digress from this well established 
scoring method by doing just a "quick-scan" for mitotic figures, tllis would affect the 
prognostic estimation and would negatively influence the choice of treatment (Skaland, 
van Diest, Janssen, Gudlaugsson, & Baak, 2008). Other studies suggest that using this 
method of grading is non-reproducible and should be replaced with one which measures 
t11e proliferative rate (Meyer et al. , 2005; Tawfik et al. , 2007). Both Ignatiadis et. al. 
(2008) and Sotiriou et.al. (2006) suggest that the category for moderately differentiated, 
grade II, tumors should be removed from the system. In this then, tumors would be 
classified as either low grade (good prognosis) or high grade (poor prognosis). The 
current grading system has been challenged in many respects, however, it is thought that 
when a system is used consistently and universally, then with increased experience and 
training the system will become more reproducible. 
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1.3 Estrogen and the Estrogen Receptor 
As mentioned earlier, estrogen and progesterone are steroid hormones which 
are critical for a number of physiological processes, including mammary gland growth 
and development (Anderson, 2002). Estrogen is produced through a process known as 
steroidogenesis, with cholesterol as its starting molecule. These hormones are produced 
primarily by the ovary and the fetoplacental unit. To a lesser extent they are produced in 
the adrenal gland, liver and mammary glands. 
1.3.1 Estrogen Receptor: A Nuclear Hormone Receptor 
Estrogens have low solubi lity in aqueous solutions and exist in circulation as 
biologically inactive complexes or as free (unbound) and active (Nussey & Whitehead, 
2001 ). 17~-Estradiol (E2) is one of the three major estrogens and has the most influence 
on the growth and development of the breast. It travels by way ofthe circulatory system 
to its peripheral target tissues, it is within these tissues that the hormone interacts with it 
cognate receptor (estrogen receptor) thereby stimulating a series of biological events. In 
some cases estrogen is produced locally within the target tissue; breast tissue is one such 
example. In this case, steroid precursors are first recruited from circulation and it is within 
the breast tissue that estrogen synthesis is completed (Foster, 2008). 
There are two forms of the estrogen receptor, Estrogen Receptor-alpha (ERa.) 
and Estrogen Receptor-beta (ER~), which are encoded by separate genes. E2 can interact 
with either ERa. or ER~. Estrogen receptors belong to a family of receptors known as 
Nuclear Hormone Receptors (NRs) which are intracellular proteins that regulate, once 
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bound to a ligand such as E2, the transcription of target genes. Hence, they are frequently 
referred to as ligand-inducible transcription factors (Pearce & Jordan, 2004). 
While ERa has been shown to be distributed among fewer tissues within the 
body than ER~, both receptors are expressed within the normal man1mary gland (Cordera 
& Jordan, 2006). Within the mammary gland its localization is predominantly within the 
nucleus and to a lesser extent within the cytoplasm, mitochondria and the cell membrane 
(J. Q. Chen, Delannoy, Cooke, & Yager, 2004; Levin, 2002; Yang, Barnes, & Kumar, 
2004). lwao et. al. (2000) demonstrated that ERa is over expressed; in contrast Roger et. 
al. (200 I) found that ER~ is down-regulated in breast carcinomas. 
The domain structures of ERa and ER~ have significant sequence 
homology (Figure 16). Ofthe 5 domains (A/B, C, D, E and F) within the ER, it is the AlB 
domain that contains an activation function 1 (AF-1) which elicits the ligand-independent 
transcriptional activation function of the ERa and permits many protein-protein 
interactions. Juxtaposed to the AlB domain is the DNA-binding domain or the C-domain. 
It is through this portion of the receptor that it can bind to specific sequences, known as 
estrogen response elements (EREs), within target genes and activate gene transcription. 
Adjacent to this domain are the D and E domains, which are the hinge region and ligand-
binding domain (LBD), respectively. The LBO allows for ligand interaction and is 
responsible for nuclear translocation, interaction with heat shock proteins (some of which 
keep the receptor in its inactive form) and homo- or heterodimerization. In addition, the 
LBD (E-domain), in contrast to the AF -1 region, can induce ligand-dependent 
transactivation of target genes through its activation function 2 (AF-2) region (Cordera & 
Jordan, 2006; Foster, 2008). The role of the F domain, located within the C-terminus of 
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the ER, is still uncertain. However, a recent study suggests that it inhibits ligand-induced 
receptor dimerization (Yang, Singleton, Shaughnessy, & Khan, 2008) (Figure 16). 
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Figure 16 Structural domains of Estrogen Receptor a (ERa) 
The ER protein has 5 domains; AlB, C, D, E and F. Its ligand-independent 
transcriptional activity occurs through the activation function 1 (AF-1) region within 
the AlB domain. The DBD allows the protein to recognize and bind to specific target 
gene sequences known as estrogen response elements (EREs) and induce gene 
transcription. The D domain is the hinge region and adjacent to this domain is the 
LBO that houses numerous responsibilities such as ligand-dependent transcriptional 
activation, dimerization and nuclear translocation. The F-domain is a variable 
region. (Pearce, S. T., & Jordan, V. C., 2004) 
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1.3.2 ER Models of Function 
Estrogen can exert its transcriptional activation capabi lities through both 
genomic (classical) and non-genomic (non-classical) processes. Being a steroid hormone, 
estrogen is lipophillic, thus permitting it to cross the lipid bilayer of the cell membrane. 
Once inside the cell it can bind to the ER within the cytoplasm or within the nucleus. 
In the classical model (Figure 17 A), the estrogen receptor undergoes a 
conformation change upon binding to a ligand such as E2. After which, it then forms a 
homodimer and translocates to the nucleus. In this mode of action, the homodimer will 
bind to the EREs located with in the target gene(s) and recruit co-activators, which is 
subsequently followed by initiation oftranscription. 
The explanation described above is a simplistic one since what actually takes 
place in the classical model involves many protein-protein interactions between the ER 
and other agonist and antagonists. When not bound to either of these, the ER will interact 
with a co-repressor, which will act to prevent the ER from initiating transcription (Nilsson 
et. al., 2001). 
ER can also act through non-classical modes of action. In that, it is capable of 
eliciting a growth or proliferative response without directly interacting with the DNA. 
Initially, it was thought that the only way in which ER elicted transactivation was through 
direct interaction with DNA through ERE. However, it is now known that the ER can 
activate transcription of target genes indirectly. In that, activated ERs can interact with 
other transcription factors and hence participate in the regulation of target gene 
transcription. 
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ERE-mode Spl-mode APt-mode NFKB inhibition 
E2 
Figure 17 
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Modes through which ER can exert it gene transactivation 
capabilities 
Classical mode of action whereby the ER will interact with ERE of target genes, upon 
binding of its cognate ligand (Estradiol, E2), to induce their transcription (A). The ER 
also acts to induce transcription of target genes without directly binding to DNA, 
rather it interacts with other proteins (Spl (B), Apl (C), NFKB (D)), in addition to E2, 
to influence gene transcription. (Nilsson S. , et. al. 2001) 
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1.3.2 ER Models of Function (continued) 
For example, ERa can interact with the c-rel subunit of the NFtcB complex and 
prevent NFtcB from binding to target gene promoters such as Interleukin-6 (IL-6) and 
hence its transactivation (Nilsson et al, 2001). 
Both types of the estrogen receptor can interact with Sp1; following translocation 
to the nucleus the E2/ERa complex binds to Sp 1 which in turn binds to specific sequences 
in the promoter regions to initiate transcription oftarget genes such as RARal , Hsp27, 
E2Fl, cyclin Dl, Bcl-2, VEGF (Figure 17B) (Nilsson et al. , 2001; Safe & Kim, 2008). 
RXRal is known to have an increased expression in ERa-positive breast cancer cells and 
play a role in increased cell proliferation of such cells. It is also a target of many drug 
therapies designed to combat E2/ERa/~-induced breast cell proliferation (Sun, Porter, & 
Safe, 1998; Zou et al. , 1999). Hsp27 has a cytoprotective role and has been shown to 
enhance chemoresistance in some cancers (McCollum, Teneyck, Sauer, Toft, & 
Erlichman, 2006). CyclinD1 is a positive regulator of cell cycle progression and Bcl-2, as 
previously mentioned, is an anti-apoptotic protein. Finally, VEGF is a signaling protein 
that initiates new blood vessel growth, allowing neoplasms to grow in size and a method 
oftraveling to other sites within the body. Hence, ER-Sp1 transcriptional pathway is 
associated with breast cell growth, chemoresistance and metastases. 
The ERa and ER~ can induce gene transcription via interactions with the specific 
proteins, fos and j un, that are part of the larger Ap 1 complex (Figure 17C). The 
interaction of ERa or ER~ is one which enhances Ap 1 activity in the presence of E2• 
E2/ERa complexes enhance gene transcription through recruitment of Ap 1 co-activators 
(p 160 fami ly), whereas E2/ER~ enhances Ap 1 activity thmugh release of co-repressors 
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from the Ap 1 complex (Paech et al., 1997; Philips, Chalbos, & Rochefort, 1993; Webb et 
al., 1999). 
ER also acts to inhibit transcription of IL-6, thus negatively regulating cell 
proliferation, through interaction with the c-Rel of the Rel/NFKB complex (Figure 17D) 
(Galien & Garcia, 1997). The inactive form of the Rei/NFKB complex within the 
cytoplasm (through its interactions with cytoplasmic inhibitory proteins) becomes active 
upon both through degradation/release of such restrictive proteins and translocation to the 
nucleus. This subcellular localization then allows Rel/NFKB to activate transcription of 
target genes such as the pro-tumorgenic IL-6; an action which is inhibited by the 
interaction of ER with the Rei portion of the complex. IL-6 acts to decrease tumor cell 
apoptosis and increase their angiogenic protentiaJ, both of which contribute to cancer cell 
growth and metastases (Lukaszewicz, Mroczko, & Szmitkowski, 2007). In this 
circumstance, ER acts to prevent the formation of neoplasms. 
ER can also be activated through a number of other ligand-independent, signal 
transduction pathways, such as the mitogen activated protein kinase (MAPK) pathway. 
Once activated, through overexpression of HER2 ( Human Epidermal Growth Factor 
Receptor 2, erb2 or HER2), the MAPK can in turn activate the ER through 
phosphorylation. The ER can then initiate gene transcription (Clarke, Anderson, & 
Howell, 2004; Kato et al. , 1995; Thomas, Sarwar, Phoenix, Coombes, & Ali, 2008). 
Song, et. al. (2007) also reportER involvement in a Membrane-initiated steroid 
signaling (MISS) pathway. Thjs is regarded as an extranuclear ER role, in which the 
receptor forms a rapid and transient complex with many signaling molecules. In response 
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to t.z, thiS complex leads to act1vat1on ot the MAPK and akt pathways; stgnalmg wh1ch 
1.3.3 ER-alpha and Breast cancer 
. . . . . . . .. 
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that, their development arises, largely, due to the presence of genomic/non-genomic 
growth promoting activities of nucl ar hormones and mil::kar hui"iiivii~,.. i"~'--'~,..f!iut.:. .:.u'--':1 a.:. 
estrogen and the estrogen receptor, respectively. There is a differential expression of ERa 
in normal breast tissue and breast carcinomas. ln normal tissue, ERa is expressed at low 
levels in non-proliferating epithelial cells, but in hjgher amounts in proliferating breast 
twnors (Fowler & Alarid, 2007; Holst et al., 2007). It is also known that benign, 
proliferative breast diseases and invasive breast carcinomas have a higher ERa expression 
compared to non-proliferative disease. There are many mechanisms which might account 
for such increases including amplification of the ERa gene, ESRJ (Fowler & Alarid, 
2007; Holst et al. , 2007). 
The E2/ERa complex can, in part, lead to the development of a breast 
neoplasm through stimulating the transcription of genes that are responsible for increased 
cell growth and differentiation. More specifica lly, the complex can drive the transcription 
of genes that give rise to growth promoting proteins (Peri llo, Sasso, Abbondanza, & 
Palumbo, 2000; Savicky, 2004). 
As discussed in the previous section, Bcl-2, VEGF, cyclinDl are common 
transcriptional gene targets of the E2/ERa complex. Transcription of the PR gene can also 
be induced through ERa-dependent pathways or through E2/ER-independent pathways 
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(Lee & Gorski, 1996; Nardulli, Greene, O'Malley, & Katzenellenbogen, 1988). The role 
ofPR in the development ofbreast cancer is still controversial (Lange et aJ., 2008), but 
many agree that it promotes increased cell cycle progression (Kariagina, Aupperlee, & 
Haslam, 2008). Two other proteins that contribute, under normal circumstances, to the 
advancement of breast cells from G 1 to S phase transition of the cell cycle are cyclin Dl 
(discussed previously) and c-Myc. However, when either these are overexpressed as a 
result of increased ER-dependent gene transcription, cells will progress through the cell 
cycle at an abnom1al rate. This may result in an increase in the number of genetic 
mutations and development of malignant growth (Butt et al., 2008). 
There are a number of cofactors that associate with the ER to either fosterER-
dependent transcription (coactivators) and inhibit it (corepressors). SRC-3 and TRAP220 
are ERa. coactivators, whereas NCoR (Nuclear Receptor Corepressor) is a corepressor 
(McKenna, Lanz, & O'Malley, 1999; Nilsson et al. , 2001). A change in the level or 
pattern of expression of such cofactors can give rise to a malignant breast tumor through 
deregulated ERa-dependent transcription. 
Many therapies have been designed to combat breast cell growth with goal of 
either reducing the tumor burden or as a preventative measure for recurrences. Such 
therapies include those that alter the level of estrogen (aromatase inhibitors) and those 
which alter ERa. by inhibiting the binding of its ligand and/or its co-activators. The latter 
of which are collectively known as Selective Estrogen Receptor Modulators (SERMs) 
(Lo & Vogel, 2004). Other studies suggest that resistance to SERMs maybe due to Akt or 
MAPK pathway aberration and cross-talk with components ER pathways. Hence, 
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targeting such pathways may be a suitable target for those who develop a resistance to the 
traditional treatment regimes (Sengupta & Jordan, 2008). 
In summary, the last two sections explained how ER acts to induces gene 
transcription and how deregulation of such can promote mammary carcinogenesis. The 
ER-dependent transcriptional pathways have a number of regulatory processes such as 
phosphorylation of ERa, binding of corepressors and/or coactivators as well as crosstalk 
with other pathways. It has been established that breast carcinomas, which occur under 
the influence ofE2 and ERa, arise through a cumulation of deregulated regulatory events. 
Aside from the endogenous effects of E2 and the ER, a study by Rohan et. aJ. 
(2008) of 16,608 post-menopausal women found that those who take synthetic estrogen 
and progesterone were at an increased risk for benign proliferative breast disease and 
subsequent development of invasive breast carcinoma. The result of such studies has 
brought about a public awareness that often deters women from taking medications that 
are designed to curb menopausal effects. 
1.4 MI-ERla 
Mesoderm Induction Early Response 1 (MI-ERl) was found to be an 
immediate-early gene, or an initial target of signal transduction, during Fibroblast Growth 
Factor (FGF) signal transduction. MI-ER1 is a novel protein that was discovered during 
the investigations into the role of FGF in Xenopus laevis embryonic cell differentiation 
(Paterno, Li, Luchman, Ryan, & Gillespie, 1997). During these investigations, Paterno et. 
al. (1997) demonstrated, using Xenopus explants, that MI-ERl levels are increased 
following addition ofFGF. 
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In an effort to characterize human mi-er I (hmi-er 1), the human orthologue of 
xrni-er 1 was cloned by Paterno et. al. (1998, 2002) and was found to be a 63kb, single 
copy gene located on chromosome 1. 
1.4.1 MI-ERl Structure 
The hrni-er 1 gene gives rise to 2 major protein isoforms a and ~(Figure 18) 
(Paterno et al., 2002). The a C-terminus is 23 amino acids long, in contrast the ~ C-
tenninus is 102 amino acids in length and includes the facultative intron 15 (Paterno et 
al. , 2002). 
It was noted when comparing hMI-ER1 with the XMI-ER1 that there was 91% 
sequence similarity overall, with some regions displaying 100% identity, indicating a 
highly conserved protein. 
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Figure 18 Structure ofMI-ERl 
The two hMI-ERl isoforms hMI-ERla and hMI-ERl~ (A). The acidic activation 
domain, ELM2 and the SANT domains are a part of a common internal region to 
both protein isoforms. The amino acid sequences for the two alternate C-termini of 
MI-ERl, a and~ (B). 
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1.4.2 MI-ERl Functional Domains 
Both the structure and sequences ofMI-ERI were compared to other known 
proteins to see there were any functional domains from which one could infer MI-ERl 's 
function. Indeed, several domains that are common to transcriptional regulators were 
identified (Figure 18). 
A: Acidic activation domain: This is a domain that is, by definition, rich in acidic 
amino acids and in the MI-ERl protein is located near theN-terminus. Paterno et. al. 
(1997) identified four stretches that were rich in acidic amino acid residues. Acidic 
activation domains are commonly known to participate in the recruitment of 
transcriptional machinery and therefore initiate gene transcription (Melcher, 2000). 
B: ELM2 domain: The EML2 domain immediately adjacent and downstream from 
the acidic activation domain. It is a domain that has been identified in other proteins that 
function as transcriptional regulators; specifically, this domain permits proteins to recruit 
and bind to other proteins that act to suppress gene transcription (Ding, Gillespie, & 
Paterno, 2003). Recruitment of the transcriptional repressor Histone Deacetylase 1 
(HDACl) to MT-ERl occurs through the ELM2 domain. Histones are proteins around 
which DNA winds, compacting the genome and thus permitting it to fit within the small 
confmes of a cell ' s nucleus. HDAC is an enzyme with an ability to remove acetyl groups 
from lysine residues of histone proteins. When this occurs the chromatin, that was once 
uncoiled, becomes more tightly wound onto the histone protein, inhibiting the 
transcriptional machinery, hence inbihiting gene transcription. 
CREB-binding protein (CBP) is a transcriptional co-activator that has intrinsic 
histone acetyl transferase (HAT) activity. HATs add acetyl groups to lysine residues of 
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histone proteins and allowing for the uncoiling of DNA, thus enabling gene transcription. 
The addition of acetyl groups neutralize the positive charged associated with the lysine 
residues which therefore reduces the affinity that the negatively charged DNA has for the 
histone proteins. Recently, it was found the Ml-ERl interacts with CBP through both its 
acidic activation domain and its ELM2 domain and prevents CBP from exerting its HAT 
activity. Hence, this represents another pathway through which Ml-ER1 is able to act as a 
transcriptional repressor (Blackmore, Mercer, Paterno, & Gillespie, 2008). 
C: SANT domain: C-terrninal to the ELM2 domain within MI-ERl is the SANT 
domain, which was so named following its initial identification in .S.WB, ADA2, NCoR 
and IFIIIB transcriptional factors. SANT domains allow for DNA binding and protein-
protein interactions, including HDACs (Aasland, Stewart, & Gibson, 1996). This domain 
was also found in transcription regulatory molecules and complexes, such as SMRT 
(Ordentlich et al. , 1999) and MT A-1 (Toh et al. , 2000), respectively. 
Spl is a transcription factor that recognizes and binds to GC rich areas within the 
promoters of target genes, recruits the TFJID complex and together initiate gene 
transcription (Kolell & Crawford, 2002; Song eta!., 2003). Ding et. a!. (2004) found that 
the SANT domain within MI-ERl allows for its interaction with Spl; an interaction that 
prevents Spl from binding to the promoters oftarget genes and thereby inhibits its 
transactivation capabilities. 
D: Proline rich region: Many signaling proteins bind to proline-rich region within 
other proteins through SH3 domains. A small protein motif is defined by the sequence 
PXXP, with P representing a Proline and X representing an amino acid. Such a region has 
been identified in both XMI-ERl and hMI-ERl and Teplitsky et. al. (2003) demonstrated 
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that only proline 365 is imperative to the role that MI-ERl plays in Xenopus embryo 
development and mesoderm induction. 
E: NLS signal: Ml-ERl~ contains a nuclear localization signal (NLS) within the C-
terminus (Post, Gillespie, & Paterno, 2001 ). NLSs are short segments of amino acids 
located on the surface of certain proteins that are recognized by cytosolic nuclear 
transport receptors which mediate the transport of the protein into the nucleus. In contrast, 
MI-ERla does not contain a NLS and therefore relies on binding to other proteins that do 
contain such sequences in order to move into the nucleus. 
F: LXXL motif: Many nuclear hormone co-activators (e.g. SRC-1 and CBP) and co-
repressors (e.g. NCoR) contain a domain, known as a NR box or a LXXLL domain 
(where L represents a leucine residue and X represents any amino acid), that permits it to 
bind to NRs. Such a domain has been identified within the C-terminus ofMI-ERla. 
LXXLL domains can confer both co-activator and co-repressor activities within a 
single protein (Sauve et al., 200 I). MICoA (MT A !-interacting coactivator) binds to the 
ER, through the interaction of the LXXLL domain of the MICoA protein and the AF-2 
region ofthe ER, to stimulate ER-driven transcription. Repression ofthis MICoA-
mediated ER transactivation can occur when MTA binds to the LXXLL domain of 
MICoA, thus preventing it from binding to the ER and acting as a coactivator (Mishra et 
al., 2003). 
1.4.3. Previous work: MI-ERla 
Human embryonic kidney cells (HEK293), transfected with both mi-er 1 a and 
era, were used to determine if Ml-ER 1 a and ERa physically interact with one another. 
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Co-immunoprecipitation assays revealed these proteins do indeed interact in the presence 
and absence of its ligand E2 and this interaction is stronger in the absence ofE2 
(McCarthy et al. , 2008) (See Appendix B, Figure lA). 
Extracts from an MCF -7 cell line, ER positive breast carcinoma cells, were 
used to investigate the endogenous interaction between Ml-ER1 a and ERa. Supporting 
the results ofthe transfected assays, endogenous Ml-ERla and ERa were shown to 
interact (See appendix B, Figure lB). Again, this interaction was observed to be stronger 
in the absence of E2 (McCarthy eta!., 2008). 
Anchorage-independent growth is an acquired characteristic of many tumor 
cells which provides them with the ability to grow without adhering to the substratum; a 
characteristic which distinguishes cancer cell proliferation from normal cell proliferation. 
As previously stated Ml-ERla was shown to possess domains that are characteristic of 
co-activators and co-repressors, hence investigations into the ability ofMI-ERla to 
repress ER stimulated cancer cell anchorage-independent growth was carried out using 
soft agar assays. Using a doxycycline-inducible MI-ERla T47D breast cancer cell line, 
overexpression ofMl-ERla was shown to suppress ERa-induced colony growth in soft 
agar (See Appendix B, Figure 2) (McCarthy et al., 2008). 
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1.5 Hypothesis and objectives 
Elucidation of all steps, as well as the regulatory factors, within the ERa 
transactivation pathway is essential for the development of early detection/screening 
markers and tests, prognostic indicators and more effective treatment strategies. It is now 
known that Ml-ERla interacts with ERa and negatively influences breast carcinoma cell 
proliferation. In particular, it has been shown to suppress ERa activity in a variety of 
breast carcinoma cell lines. It is also known that MI-ERla contains an LXXLL domain 
that is common to many NR co-activators and co-repressors. 
From this, it is hypothesized that MI-ER I a is a key factor in the regulating the 
activity of ERa and hence ERa-dependent tumor growth. Before identifying MI-ERla as 
a potential therapeutic agent or its use as a prognostic indicator, its expression in human 
normal and neoplastic breast tissue ftrst needs to be determined. The specific aims of this 
study were: 
1. To determine the expression of MI-ERl a in whole tissue sections of human breast 
carcinoma and adjacent normal cells. More specifically, we wanted to determine the 
average level of expression and the proportion of cells expressing MI-ERla in both the 
tumor and the adjacent normal cells. In addition, we wanted to determine the 
expression ofMI-ERla in normal breast tissue; breast tissue from patients not having 
had breast carcinoma or having a family history of such. 
2. To compare MI-ERla expression level in human breast carcinoma tissue to that of 
adjacent normal breast tissue to determine if a differential in the expression exists 
between the two. 
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3. To determine ifthere is a correlation between the expression level and 
clinicopathological parameters such as tumor size, grade, stage, and hom1one receptor 
positivity. 
4. To determine the subcellular localization of MI-ERla in whole tissue sections of both 
human normal breast tissue and human breast carcinoma. As well as examination of 
such in tissue microarrays (TMAs) of human normal breast tissue, breast carcinoma 
and various breast pre-invasive subtypes. 
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2. MATERIALS AND METHODS 
2.1 Patient Selection 
As outlined in the objectives for this project, Section 1.5, an investigation of: (1) 
the expression in normal breast tissue (from cases having no history of cancer) and (2) a 
comparison of expression between tumor cells and adjacent normal ductal or lobular 
epithelium within breast tumor samples was to be carried out. The normal breast samples 
were archived samples of tissue removed from patients who had a reduction 
mammoplasty. Both the criteria and the process of selection for the tumor samples differ 
from that for the normal samples, as such they are discussed separately in the pages to 
follow. Sections 2.1.3 - 2.1.5 detail the selection process for the tumor samples and 2.1.6-
2.1.8 explain the selection process for the normal samples. This study was approved by 
both HIC (HIC approval No. 05.56) and RPAC. 
2.1.1 Time Period and Hospital Selection - Normal and the Tumor Samples 
Formalin-fixed paraffin embedded breast tissue specimens archived at St. Clare' s 
Mercy Hospital and the Health Science Center (HSC), St. John 's, Newfoundland and 
Labrador were chosen for this study. 
The time period chosen for this study was 2005 - 2006, inclusively. Specimens 
within this time period were the most recently fixed and processed at the time of selection 
and therefore any concerns regarding tissue degradation were minimized. Secondly, for 
the years of 2005 onward, the protocol for fixation and processing had been identified as 
consistent for both of the aforementioned hospitals. In that, St. Clare's and the Health 
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Sciences Center were using the same protocol for fixation and processing of the samples. 
Therefore, differences observed would not be attributed to differences in fixation and 
processmg. 
2.1.2 Database and Pathology Reports- Breast Tumor Samples 
A database of all breast cancer cases diagnosed at either the St. Clare' s Mercy 
Hospital or the HSC between January 151, 2005 and December 31 51, 2006 was obtained 
from the NL Eastern Health Cancer Registry. All of the invasive ductal carcinoma (IDC) 
cases were extracted from this database and pathology reports were retrieved for each of 
these cases. Pathology reports for each case were reviewed to ensure: 
I. That all of the cases were an IDC and not a mixed tumor having a 
morphological appearance of both lobular and ductal carcinoma. 
II. That the archived specimen under review was the primary cancer and not a 
recurrence of breast cancer or a metastatic cancer. 
III. That this report is associated with whole tissue sections of the lesion in 
question and not a biopsy sample. In that, these samples were a resection 
specimen and not a needle core biopsy sample. 
IV. That these cases were accessible from either St. Clare's Mercy Hospital or 
the HSC and were not associated with a referral from an outside hospital. 
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V. That cases were only selected if the pathology report had stated that the 
standard test for ER/PR was carried out at Mount Sinai Hospital, Toronto, 
Ontario. 1 
Any cases not meeting the above criteria during this review process were excluded 
from the study. 
2.1.3 Criteria for Specimen Selection-Breast Tumor Samples 
Prior to selection of the cases that were to be used for this study, four criteria were 
established: 
I. That upon review of the hematoxylin and eosin (H & E) stained slides, which 
contained a 4 or 5j.!m thick representative of archived, paraffin-embedded breast 
tumor tissue, only those which were both adequately fixed and processed prior to 
being embedded in paraffin were selected. Adequate fixation and processing is 
based upon the morphological appearance of the cells. One sign of poor fixation is 
when the cells appear to be detached from the connective tissue and surrounding 
cells. Appropriate inclusion of each sample, based on this criteria, was determined 
by pathologist Dr. Bev Carter. 
II. To compare the expression between tumor cells and that of the adjacent normal 
cells, only cases with ample amounts of both tumor cells and adjacent normal 
ductal epithelium were selected. 
1 Due to the Estrogen Receptor (ER) and Progesterone Receptor (PR) retesting of breast 
carcinoma cases here in NL, for a time period that includes 2005, Mount Sinai's 
pathology department was the selected hospital for retesting until quality control within 
the pathology department of Eastern Health was established. 
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III. Only blocks that contained copious amow1ts of breast tissue were selected; which 
was done as a means to avoid exhaustion of the san1ple. In this regard, samples 
were preserved for future clinical purposes. 
2.1.4 Number of Cases used in the Study-Breast Tumor Samples 
This was a retrospective study in which an initial129 IDC cases were identified 
from the Cancer Registry database. Pathology reports for all 129 cases were reviewed and 
cases not meeting criteria I-IV, as identified in section 2.1.2, were excluded from the 
study. One hundred and nineteen cases were identified after review of the reports. For 
each of the 119 cases selected up to this point, H & E stained slides were retrieved and 
reviewed with pathologist, Dr. Beverly Carter of Eastern Health. Only those cases that 
fulfilled the specimen selection criteria identified in section 2.1.3 were included in the 
study; the study cohort for this project consisted of 110 women diagnosed with primary 
IDC. For each case, one archived, formalin-fixed, paraffin-embedded block of breast 
tumor tissue was selected and retrieved from storage at either St. Clare's Mercy Hospital 
or the HSC (Figure 19). 
2.1.5 Database and Pathology Reports- Normal Breast Tissue Samples 
To investigate the expression in normal breast tissue with no history of breast 
cancer, a list of patients having had a reduction man1moplasty between January 1 5', 2005 
and December 31st, 2006 were obtained from the Pathology department. Pathology 
reports for all these cases were retrieved and reviewed; cases meeting all of the following 
criteria were added to a database: 
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I. Only cases that had archived, normal breast tissue as a result of having a 
reduction mammoplasty were selected. In that, those having archived 
nom1al tissue as a result of a mastectomy due to an increased risk for 
breast cancer were excluded from the study. 
II. Only patients with no history of hyperplasia, Ductal Carcinoma in Situ 
(DCIS) or breast carcinoma were selected 
III. Cases with no family history of breast carcinoma were selected 
IV. Microscopic findings detailed in the pathology report must not describe 
any of the following proliferative breast abnormalities as detailed in 
Table 1: 
a. Proliferative diseases without atypia 
b. Proliferative disease with atypia 
c. In Situ lesions 
Ensuring that there was no history of that listed above was done as a means to 
increase the validity of the results; that any analysis of the normal tissue were not due to 
the influence of other cellular changes within the breast tissue. 
2.1.6 Criteria for Specimen Selection-Normal Breast Samples 
Before selecting the normal breast specimens to be used in this study, three criteria 
were established: 
I That upon review of the hematoxylin and eosin (H & E) stained slides, which 
contained a 4!Jlll thick representative of archived, paraffin-embedded normal 
breast tissue, only those which were both adequately fixed and processed prior to 
76 
being embedded in paraffin were selected. 
II To determine the expression pattern in nom1al breast tissue, specimens 
which contained sufficient amount of and only normal ductal epithelium were 
selected. 
III Only blocks that contained copious amounts of breast tissue were selected; 
which was done as a means to avoid exhaustion of the sample. In this regard, 
samples were preserved for future clinical and research purposes. 
2.1.7 Number of Cases used in the Study-Normal Breast Tissue 
All cases that satisfied the criteria outlined in sections 2.1.5 were subsequently 
added to a database. From this database 60 cases were randomly selected using a random 
integer generator located on the World Wide Web (http://www.random.org/integers/). 
The H & E stained slides for each case were reviewed with pathologist, Dr. 
Beverly Carter of Eastern Health. During the review of these slides, the diagnosis and 
microscopic descriptions detailed in the pathology report were confirmed and one 
archived, formalin-fixed, paraffin-embedded block of normal breast tissue was selected. 
As a consequence of the selection criteria delineated in section 2.1.6, 14 cases were 
excluded from the study. For each of the 46 cases, one archived formalin-fixed, paraffin-
embedded block of normal breast tissue was retrieved from storage at either St. Clare's 
Mercy Hospital or the Health Science Center (Figure 19). 
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Figure 19 
Patient Selection 
Database review 
Normal breast: Reduction mammoplasty (504 cases) 
Breast carcinoma: Primary IDC (129 cases) 
~ 
Confirm no other abnormality 
~ 
46 Normal Cases 
110 !DC Cases 
Process for selecting cases of normal breast tissue and primary 
lDC. 
Database and pathology reports for all cases between 2005-2006 were reviewed to 
confirm that normal cases were strictly reduction mammoplasties and the tumor cases 
were primary IDC cases. It was also confirmed using the reports that there were no other 
abnormalities. H&E slides were reviewed to confirm adequate fixation and paraffin 
blocks were subsequently retrieved. 
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2.2 Tissue Microarrays (TMAs) 
2.2.1 Number of Cases Used in the Study-TMAs 
Fourteen breast Tissue Microarrays (TMAs) were acquired from BioChain 
Institute Inc. (Hayward, California, U.S.), US Biomax Inc. (Rockville, Maryland, U.S.) 
and the Cooperative Human Tissue Network (CHTN) (Columbus, Ohio, U.S.) . In total, 
these TMAs contained 204 normal breast, 78 DCIS, 102 Invasive Lobular Carcinoma 
(ILC) and 343 IDC cases. 
2.2.2 Tissue Microarray Construction 
All TMAs used in this study were constructed by the manufacturer. Briefly, a 
fresh section of the donor block (the original paraffin-embedded tissue) is made and 
stained with H&E. An optimal area of the tissue block from which to extract the core is 
selected by a pathologist upon review of the H&E slide; this area is then circled on the 
corresponding donor block to localize the region (Shergill, Shergill, Arya, & Patel, 2004). 
A grid, or sector map, which details the location of each core on the TMA is planned and 
used as a guide to construct and score the TMA (Voduc, Kenney, & Nielsen, 2008). This 
sector map also provides a link to the donor block and hence, experimental results can be 
rapidly compared to the clinicopathological characteristics associated with each case 
(Shergill et al. , 2004). A core, ranging in size from 0.6mm to 2.0mm, is removed from a 
blank paraffin block (recipient block) and is replaced with a core from the target area of 
the donor block (Figure 20) (Voduc et al. , 2008). 
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Figure 20 
Fresh H + E section 
Finished TMA block 
TMA Construction 
Original block 
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Each core of TMA originates from an area of interest located on a donor block after 
review of the corresponding H&E section. A core of is removed from a blank paraffin 
block and replaced with a core from the donor block (Shergill , I.S., 2004). 
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2.3. Tissue Fixation and Processing 
The most important step in preserving human tissue, is fixation. Fixation is an 
attempt to preserve the natural state of the tissue as much as possible. Fixation and 
processing for the WTS is described below in section 2.3.1 and in Appendix C for the 
TMAs. 
2.3.1. NL Normal and Tumor Breast Tissue 
All paraffin tissues used in this study were fixed and processed by the pathology 
laboratory staff at either St. Clare's Mercy Hospital or the HSC according to the 
"Fixation Procedure for Pathology Specimens", Section No. PRC-PAT-102, within the 
HSC Pathology Division' s "Anatomical Pathology/Specimen Collection and Handling" 
manual, written by the Quality Management Coordinator of the Pathology Division, 
Catherine Parnell. Briefly, the specimen is placed in a 10% buffered Formalin (a 4% 
formaldehyde solution) within 30 minutes of removal from the body. The specimen is 
placed in volume of formalin that is 10 times that of the tissue; for small tissues this 
incubation is between 3 and 24 hours and 24-48 hours for large tissues (Parnell, 2008). 
The tissues are then inserted into specimen cassettes and placed into an automatic Tissue 
Tek VIP 5 Vacuum Infiltration Processor (Sakura Finetek USA, Inc.). Cassettes are 
placed into a retort where reagents and molten paraffin move in and out sequentially via 
vacuum and pressure. This processor has a closed system design, which allows for 
reduced air exposure to the tissues. Processing of the tissues involves dehydrating, 
clearing and then infiltration of the tissues samples. First is the dehydration step, whereby 
water is gradually removed from the tissue through immersion in various grades of 
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alcohol and finally replaced with 100% alcohol. Secondly, the alcohol is cleared in 
Xylene and replaced with a solvent that is miscible with wax. The tissue is then infused 
with a paraffin wax which removes the clearing reagent and results in a hardened tissue 
that facilitates cutting of the tissue into sections. Finally, the tissue, which is engrossed in 
a paraffin wax within a tissue cassette, is then sectioned and stained with H&E prior to 
being archived and stored for future use. The H&E slides are examined by pathologists 
during their diagnostic procedures, following which, the slides are archived along with 
the paraffin tissue blocks. 
2.4 Slide Preparation and IHC Pre-treatment 
A NL Normal and Tumor Breast Tissue 
Four 4pm think sections were cut (by P. McCarthy) from each of the selected 
blocks and transferred to positively charged slides (Fisher); such tissue sections are 
referred to as Whole Tissue Sections (WTS). Most animal tissues cany an overall net 
negative charge due to a small excess of acidic amino acids over basic amino acids in the 
structural proteins. Hence, tissue sections can be expected to adhere well to a surface that 
has been treated in such a way as to make it positively charged (Lloyd & DeLellis, 2001 ). 
Slides are left overnight at room temperature (RT) and placed at 58°C for one hour prior 
to the start ofiHC. This is done to aid in the removal of the paraffin and hence antigen 
exposure. 
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B TMAs 
TMAs were constructed as described in section 2.2.2. The TMA block was 
sectioned, by the manufacturer, Sf.!m thick and transferred to positively charged slides. 
As was the case for the whole tissue sections, TMA slides from Biochain and CHTN were 
placed at 58°C immediately before the commencement ofiHC. TMA slides from 
Biomax are wrapped in a thin layer of paraffin and supplied in this manner in an effort to 
prevent oxidation and decay. As a result of this paraffin layer, slides needed to be baked 
at 60°C for two hours (as per the manufacturer's recommendation) prior to the start of the 
IHC protocol. 
2.5 Immunohistochemistry 
2.5.1 Primary Antibody 
The anti-MI-ERla antibody used in this study generated through the 
immunization of rabbits with a short, synthetic peptide (amino acids 41 3 - 426) of the MI-
ERl protein sequence (Paterno et a!. , 2002). The peptide sequence used was 
4 13CQMLLPVHFSATSSR426. A Melon GellgG purification kit (Pierce) was used (by Dr. 
Laura Gillespie) to purify MI-ERl IgG from both pre-immune and immune rabbit serum. 
Specificity of the MI-ER 1 a anti body was verified through an anti body pre-
absorption assay using the alpha-specific peptide used to generate the MI -ER 1 a, as well 
as an unrelated (control) peptide. Whole tissue sections of breast carcinoma were stained 
concurrently with either pre-immune IgG, anti-MI-ERla lgG, anti-Ml-ER1 a lgG pre-
absorbed with 0.1 f.!g of the a-specific peptide or anti-MI-ERla IgG pre-absorbed with 
0.1 f.!g of an unrelated peptide (amino acids 466-480 of the MJ-ER 1 ~ C-terminus). 
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Sections were first deparaffinized, hydrated and antigen retrieval was carried out as 
detailed below in Section 2.6.3. One hundred ng of each the specific and unrelated 
peptides were dissolved in a 1% Bovine serum albumin/Phosphate buffered saline 
(BSA/PBS) solution (Sigma-Aldrich, Canada, see Appendix A for recipe). The anti-MI-
ERla IgG was then diluted in this solution to 1 :800; the same dilution used for the 
experimental sections. The IgG was incubated with each of the peptides on ice, for 30 
minutes, prior to its application on the tissue sections. 
2.5.2 Staining Kit used for WTS and TMAs 
A Universal LSAB+ System-HRP kit (DakoCytomation) was utilized in the 
immunohistochemical staining procedure for both WTS and TMAs. Please see Appendix 
D for a more detail description of this kit. 
2.5.3 Immunohistochemical Protocol 
Slides were removed from the oven and deparaffinized in two changes of 
xylene for 5 minutes each and hydrated through an alcohol gradient; two changes of 
100% alcohol for three minutes each, one change of 95% alcohol for one minute and 70% 
alcohol for one minute. Slides were then rinsed in running distilled water for 5 minutes to 
complete the hydration process and to remove any residual alcohol. To quench 
endogenous peroxidase activity slides were immersed in 3% hydrogen peroxide for I 0 
minutes. To remove any excess hydrogen peroxide, slides were rinsed in running distilled 
water for five minutes. 
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Frequently antigens become masked during fixation and processing of the 
tissues; in an effort to retrieve the antigens slides were immersed in a 1 OmM citrate 
buffer, pH 6.0 (1.92g citric acid, IL deionized water, adjust pH using lN NaOH). 
Optimum antigen retrieval time was empirically determined to be 40 minutes for WTS 
and 30 minutes for TMAs. First, the citrate buffer was pre-heated to 95°C in plastic 
coplinjars and then slides were placed into the coplinjars and incubated in a 95°C water 
bath for 40 minutes (WTS) or 30 minutes (TMAs). 
Following antigen retrieval, the slides were removed from the water bath, 
retained in citrate buffer and cooled to room temperature. Slides were then rinsed in a 1 X 
phosphate buffer saline (PBS) (Sigma) solution, pH 7.4 (see Appendix E for recipe), for 5 
minutes in a humidifying chamber to prevent evaporation. 
To inhibit non-specific labeling, sections were incubated in a serum-free 
protein block (DakoCytomation) for 10 minutes. Slides were then incubated in the 
humidifying chamber overnight at 4°C with the MIERa antibody, previously described, 
diluted to 1:800 in a O.OIM PBS containing 1% weight per volume (w/v) Bovine Serum 
Albwnin (BSA), pH 7.4 (Sigma Cat. No. P3688). 
Immunohistochemical staining was continued the following day using a 
streptavidin-biotin immunoperoxidase method according to the protocol specified for the 
Universal LSAB+ System-HRP kit (DakoCytomation). First, sections were rinsed in IX 
PBS for 5 minutes to remove excess primary antibody. Sections were then incubated 
sequentially with a biotinylated link antibody and a peroxidase-labeled streptavidin for 15 
minutes each; with one 5 minute rinse in I X PBS between each incubation. After addition 
of Streptavidin, slides were again rinsed for 5 minutes in lX PBS. Slides were incubated 
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with a Liquid DAB+ Substrate Chromogen (3,3'-diaminobenzidine chromogen solution 
within an imidazole-HCl substrate buffer, pH 7.5) (DakoCytomation) for 5 minutes and 
then rinsed in running distilled water for 5 minutes. 
Sections were then counterstained in hematoxylin (Fisher) (see Appendix E for 
recipe) for three minutes and rinsed in running distilled water for 5 minutes. To 
accentuate the details of the tissue, excess dye is removed through a process known as 
differentiation by immersion for approximately three seconds in a 1% acid alcohol 
solution (see Appendix E for recipe). Next, slides were rinsed in running distilled water 
for 5 minutes, blued in Scott's tap water (see Appendix A for recipe) and rinsed again for 
5 minutes in running distilled water. 
To complete the staining, slides were dehydrated in an alcohol gradient; 1 
minute in 70% alcohol, 1 minute in 95% alcohol, then 2 changes for 3 minutes each in 
100% alcohol. Sections were then cleared in 2 changes of xylene for 5 minutes each. 
Slides were mounted using Permount media (Fisher). After allowing the Permount to dry 
overnight, sections were reviewed using a compound light microscope (Olympus BH-2) 
and pictures were taken with a coolsnap digital camera. 
2.5.4 Controls 
Included in each batch of staining, was a section of breast tissue stained with 
the pre-immune serum. This pre-immune serum was applied to the tissue at the same 
concentration and in the same diluent ( 1% BSA/PBS) as the primary antibody. All steps 
of the IHC procedure were identical with the exception that a pre-immune serum was 
applied to the tissue instead of the primary antibody. 
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Tissue sections known, from previous experiments, to give positive 
immunostaining results can be used to verify the performance of IHC reagents and the 
basic conditions of the experimental procedure (DakoCytomation, 2006). Positive and 
negative tissue controls suitable for use in this study were identified following review of 
murine tissue sections stained with an anti-MI-ER la antibody in a study by Thome et. al. 
(2008). Normal sections of the ileum from the small intestine and normal adrenal gland 
were selected as a negative and positive control, respectively. ln the previously mentioned 
study, staining was barely detectable in, and limited to, the mucosal columnar epithelium 
of the mouse small intestine; in contrast, the mouse adrenal gland was intensely positive. 
Normal human tissue sections of such were obtained from US Biomax Inc .. 
Staining of positive and negative tissue controls ensure that both the target 
antigen retrieval and staining procedures were properly carried out. It is favorable when 
the positive control contains a spectrum of weak to strong staining. If the negative tissue 
control has positive staining it indicates that either the antibody is not specific for the 
target antigen or there is non-specific binding. If both the positive and negative tissues do 
not present as expected, results from the experimental specimens should be considered 
invalid (DakoCytomation, 2006). 
For this study, whole tissue, paraffin-embedded tissue sections of human adrenal 
gland and small intestine (US Biomax Inc.) were used as a positive and negative control, 
respectively. 
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2. 7 Grading of Whole Tissue Sections and Tissue Microarrays 
All of the specimens, WTS and TMAs, were graded 24 hours after the slides were 
mounted. Grading of WTS was carried out by Dr. B. Carter and myself and the TMA 
sections were graded by Dr. L. Gillespie and myself; any cores of a questionable 
pathology were then reviewed by Dr. B. Carter. Staining was evaluated on three levels; 
the protein expression pattern, subcellular localization and the Allred scoring system. 
The protein expression pattern and subcellular localization were assessed in the TMAs 
and in both tumor and normal WTS. 
JHC is one tool used by physicians to evaluate the ER expression within breast 
tumors. It is done as a means of estimating a patient's potential response to endocrine 
treatment (predictive factor) and their expected clinical outcome or survival (prognosis 
factor) (Allred et al. , 1993; Cleator et al. , 2006; Harvey, Clark, Osborne, & Allred, 1999; 
Kurosumi, 2007). The Allred Scoring System is one such means of assessing the ER 
expression (ER status), in breast carcinoma tissue and has been widely adapted among the 
clinical pathology community (Allred et al., 1993; Harvey et al. 1999). This scoring 
system has been validated for several makers, such as ER, PR, Her2/neu and p53, and has 
been widely adapted for the use in the clinical assessment of breast tumor specimens 
(O'Malley et al. , 2001). 
In this study, staining of WTS of breast tumor were assessed using this semi-
quantitative scoring system developed by Allred et al. (1993). In accordance with this 
scoring system, all specimens were reviewed to assign a proportional score (PS) and an 
intensity score (IS), which represent the estimated proportion of positively-stained cells 
and the average intensity of positively-stained cells, respectively (Figure 21 ). 
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Representative samples of normal breast and IDC stained with the anti-MI-ERI a 
antibody and assessed using the Allred Scoring system can be seen in Figure 22. This 
figure illustrates the variability in the intensity ofMI-ERla within normal and tumor 
breast tissue and the corresponding IS assigned. 
Both the tumor and adjacent normal within the WTS were each assigned a PS and 
an IS. The PS and the IS for each of the tumor and the normal areas within the WTS were 
then added together to give an overall Allred Score; ultimately giving rise to an Allred 
Score for the tumor and an Allred Score for the adjacent nonnal. See Table 3 for the 
equivalent of each score within the Allred scoring system. The Allred Score for the 
tumor was compared with that of the normal tissue and then grouped in to one of the 
following; tumor score is less than the normal score, tumor score is equal to the normal 
score or tumor score is greater than the normal score. 
WTS and TMAs were also graded to assess the subcellular localization of MI-
ERla and then assigned to one of the three following groups; nuclear staining only, 
cytoplasmic staining only or nuclear and cytoplasmic staining. 
Prior to the commencement of the localization assessment, a cutoff point was 
determined for the consideration of positively-stained nuclei. In that, san1ples were only 
scored positive if greater than or equal to 5% of nuclei were positively-stained. 
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Scoring Immunostained Slides 
Proportion 0 - 1-(> 1/lCX>-2 -c> 1110- 3 --;> 113-4~ 213- 5 --;> 1 
Score (PS) 
lrlenstlv. 
Sco~(E) 
Figure 21 
0 = nega1ive 1 = weak 2 = in1enned 3 = s1rong 
Total Score (TS) = PS + IS (range 0-8) 
Illustration of the Allred Scoring System 
Grading of the WTS, using the Allred Scoring System, involves review of the whole 
section to first determine the estimated proportion of positively-stained cells and then the 
average intensity level for the positively-stained cells using the above illustration as a 
guide (Kurosumi, 2007). 
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Figure 22 Variable staining intensity within the cytoplasm of both normal ductal 
epithelium and breast tumor tissue 
Samples of IDC and normal breast tissue from tissue microarrays stained with anti-MI-
ER la. Variable cytoplasmic staining intensity is observable in separate cases of normal 
breast tissue are iJlustrated in panels A-C (SOX) and D-F (lOOX). Representatives of 
individual cases of IDC, also illustrating the variability in the intensity of cytoplasmic 
staining, can be seen in panels G-I (SOX) and J-L (lOOX). Intensity Score (IS) for each of 
the representative samples are as follows: negative/weak cytoplasmic staining= IS of 1, 
moderate cytoplasmic staining= IS of 2, strong cytoplasmic staining = IS of 3. Scale bar 
for panels A-C and G-I is SOf..Lm and 2Sf..Lm for panels D-F and J-L. 
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~egative/weak 
A· B· 
Weak/Moderate 
Normal 
Moderate 
Tumor 
Moderate 
Strong 
. . 
Table 3 
Intensity Score 
(IS) 
0 
1 
2 
3 
Allred Scoring System used in the assessment of MI-ERla staining of 
breast carcinoma WTSs 1 
Intensity 
Average Intensity Level: 
Positively-stained cells 
Negative 
Weak 
Moderate 
Strong 
Frequency 
Proportion Score 
(PS) 
0 
1 
2 
3 
4 
5 
Proportion of 
Positively-stained cells 
0 
<1% 
I -10% 
II - 33% 
34 -66% 
67- 100% 
1 For each case an IS and a PS was assigned; when added together it gives rise to an 
overall Allred Score within a range of 0-8. 
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2.8 Statistical Analysis 
Chi-squared analysis (Pearson's test, two-tailed, 95% confidence interval (CI)), 
using SPSS v .13 software, was used to determine if a significant correlation existed 
between various clinicopathological paran1eters and both the intensity and frequency of 
MI-ERla expression within breast carcinoma WTS. Using the two-sided Fisher' s exact 
test within the InStat v.3 software program (GraphPad Software, San Diego, USA), the 
percent nuclear staining within samples of the breast hyperplasia, DCIS, ILC, LN 
metastases and lDC was compared to that of the normal breast samples. 
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3. RESULTS 
For this study, immunohistochemistry was used in an effort to determine if there 
was a differential in both the pattern of staining and subcellular localization ofMI-ER 1 a 
between normal breast tissue and breast cancer tissue 
3.1 The anti-MI-ERla Antibody is Specific for the MI-ERla Protein 
Paterno et. al. (2002) demonstrated that the anti-MT-ER 1 a antibody specifically 
recognizes MIER 1 a through immunprecipitation and western blotting. However, for this 
study it was also important to demonstrate that this specificity extends to histological 
sections. To verify the specificity of the purified anti-MI-ERla antibody for the MI-ERla 
protein within human tissue, an antibody pre-absorption assay was carried out using WTS 
ofhuman breast carcinoma sections. Sections were stained in parallel with one of the 
following: pre-immune IgG, anti-MI-ERla antibody, the anti-MI-ERla antibody that was 
pre-absorbed with the a peptide used to generate the antibody or the anti-MI-ER1a 
antibody pre-incubated with the control peptide. This assay was performed in duplicate. 
As shown in Figure 23, staining is blocked when the antibody is pre-absorbed with the a 
peptide (Figure 23C) and results are very similar to that obtain when the section is 
incubated with the pre-immune IgG (Figure 23A). Positive staining was observed in 
sections incubated with the anti-MI-ERla antibody pre-incubated with the control peptide 
(Figure 23D) and staining was identical to that seen with the MI-ER 1 a antibody (Figure 
23B). The lack of staining observed in sections incubated with the pre-immune IgG is as 
expected since this is serum obtained prior to injection of the rabbits with the MI-ERla 
specific peptide. In other words, this is serum which, by definition, is obtained prior to 
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induction of an irnmW1e response and therefore should not contain any JgG' s that would 
give rise to immunostaining. Knowing that it is the C-terrninus which distinguishes the 
Ml-ERla isoforrn from the MI-ERl ~ isoform, that it is a peptide from the a C-terminus 
that is used to generate the antibody and that the a-peptide alone (not the control peptide) 
prevents the anti-MI-ERla antibody from binding to the tissue, indicates that the anti-MI-
ERla antibody specifically detects the MI-ERla protein in histological sections. 
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Pre-immune Immune 
Figure 23 Antibody pre-absorption assay using breast carcinoma tissue 
The MI-ER la pre-absorption assay was performed by staining whole ti sue section of 
human breast tumor with pre-immune IgG (A), anti-MIERla IgG (B), anti-MI-ERla IgG 
that was pre-incubated with the a-specific peptide (C), or anti-MI-ERla that had been 
pre-incubated with a control peptide (D). Scale bar is 50Jlm for A-D (SOX) . 
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3.2 Positive and Negative Tissue Controls 
Staining of the human positive (adrenal gland) and negative tissue (small 
intestine) controls gave similar results to that observed in the murine samples (Figure 24). 
Strong staining was observed in the in the zona glomerulosa and the zona fasciculata of 
the adrenal cortex (Figure 24A and 24C). However, immunoreactivity was absent in the 
ileum of the small intestine (Figure 24B and 24D). 
These results demonstrate the IHC procedure was satisfactory for use on these 
paraffin embedded sections and that the IHC reagents are of acceptable quality. 
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Figure 24 Immunohistochemical staining of the positive (aderenal) and negative 
(ileum) controls with anti-MI-ERl-a 
Positive and negative tissue controls included sections of adrenal gland (A and C) and 
small intestine (B and D), respectively. Sections were stained with the anti-MI-ER la 
antibody. Panels A and C exemplifies MI-ERl a expression within the zona 
glomerulosa (ZG) and the zona fasciculate (ZF). Whereas panels B and D shows a 
portion of the small intestine, the ileum, that includes crypts of Lieberkiihn "C" and 
Peyer's patch "PP" (lymphoid tissue). Scale bar is lOOflm for A and B (25X) and 
SOflm for C and D (SOX). 
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3.3 Allred Scoring Assessment ofMI-ERla Staining in Breast Cancer WTSs 
To determine if there was a difference in expression ofMI-ERla between 
breast tumor and adjacent normal tissue, WTSs of 110 primary invasive ductal breast 
carcinoma cases stained with the anti-Ml-ERla antibody were semi-quantitatively 
evaluated using the Allred Scoring System. Once staining was complete the entire section 
on each slide was reviewed by light microscopy and included in the assessment. An 
estimate of both the intensity level (Intensity Score, IS) and the proportional of positive 
cells (Proportional Score, PS) was determined for each the tumor and the adjacent normal 
tissue. When the scores were compared overall, there was no consistent difference 
between the tumor and the adjacent normal tissue. Namely, some tumors had lower 
values than the adjacent normal tissue, while others were equal to or greater than that of 
the adjacent normal tissue. The distribution of the IS, PS and Allred scores are illustrated 
in Figure 25. The average intensity, proportional and Allred score, as well as the standard 
deviation (SD), for each the tumor and adjacent nom1al are displayed in Table 4. The P 
value obtained from comparing the means of the tumor and adjacent normal is also 
reported in Table 4. 
Correlation analysis between these three categories of relative Allred Scores 
and various clinicopathological parameters was carried out using Pearson's chi-square (·i) 
test in SPSS (v.l3) software (Table 5). Clinicopathological parameters included age, 
tumor size, lymph node status, grade (modified Scarff-Bioom-Richardson), stage, as well 
as, ER, PR and Her-2/neu status. Age was broken down two ways; the first was based on 
the average onset age of menopause being 51 years (Cheung, Chaudhry, Kapral , 
Jackevicius, & Robinson, 2004) and the average age range during which menopause can 
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occur (ages 45-64) (Blumberg eta!., 1996). Results of ER and PR expression assays 
(usually through IHC), in combination with that ofHer-2/neu, are used to predict 
response to hormonal therapy and adjuvant systemic therapies such as Trastuzumab 
(Herceptin), respectively (Payne, Bowen, Jones, & Wells, 2008). As such, these 3 
markers were also included in the correlation analysis. 
A statistically significant correlation was not found between any one of the 
clinicalpathological parameters and the Allred score groups (Table 5). 
The Allred intensity and proportional scores were analyzed separately for 
correlation with the clinicopathological parameters; again, a statistically significant 
correlation was not found (Table 6, Table 7). 
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Figure 25 Distribution of the intensity, proportional and Allred scores for the 
invasive ductal carcinoma and the adjacent normal tissue 
A histogram illustrating the distribution of intensity, proportional and Allred scores for 
the invasive ductal carcinoma and adjacent nom1al breast tissue cases used in the Allred 
scoring. The intensity, proportional and Allred scores range from 0-3 , 0-5 and 0-8, 
respectively. The scores for the tumor are indicated in green and the scores for the 
adjacent normal are indicated in blue. 
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Table 4 
Mean 
±SO 
P valuea 
The average intensity, proportional and Allred score and the standard 
deviation for each the tumor and adjacent normal 
Intensity Score Proportional Score Allred Score 
Normal Tumor Nonnal Tumor Normal Tumor 
1.68 2.18 3.56 4.25 5.25 6.44 
0.787 0.756 0.130 0.923 1.81 1.35 
0.681 0.0005 0.0024 
a P value was obtained through an unpaired t-test of the intensity, proportional, Allred 
score means for each the tumor and adjacent normal. Statistical significance is assumed 
when P<O.OOOl . 
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Table 5: Correlation analysis between relative MI-ERcx staining in breast carcinoma and 
clinicopathological parameters using the Allred Scoring System 
MIER1 Expression:a Tumor Allred Score vs. Normal Allred Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total P-valueb 
Age 
<50 6 (19.4) 4 (12.9) 21 (67.7) 31 P=0.410 
>=50 8 (101.1) 16(20.3) 55 (69.6) 79 
Age 
<=44 5 (25.0) 3 (15.0) 12 (60.0) 20 
45-64 4 (7.7) 9 (17.0) 40 (75.5) 53 
>=65 5 (13.9) 8 (19.4) 24 (66.7) 37 P=0.365 
Tumor Size (TNM) 
T1 6 (10.2) 11 (18.6) 42 (71.2) 59 
T2 7 (16.7) 6 (14.3) 29 (69.0) 42 
T3 and T4 1 (11.1) 3 (33.3) 5 (55.6) 9 P=0.618 
Tumor Size (Categorical) 
<=2 em 6 (10.2) 11(18.6) 42 (71 .2) 59 
>2cm 8 (15.7) 9 (17.6) 34 (66.7) 51 P=0.693 
Lymph Node Involvement 
No 6 (13.6) 9 (20.5) 28 (63.6) 43 
Yes 4 (12.5) 6 (18.8) 22 (68.8) 32 P=0.957 
Lymph Node Status {TNM) 
NO 6 (13.6) 9 (20.5) 28 (63.6) 43 
N1 4 (16.0) 5 (20.0) 16 (64.0) 25 
N2 0 (0) 0 (0) 6 (100.0) 6 
N3 0 (0) 1 (1 00.0) 0 (0) 1 P=0.941 
Gradec 
1 6 (20.0) 8 (26.7) 16 (53.3) 30 
2 5 (11.9) 8 (19.1) 29 (69.0) 42 
3 3 (8.1) 4 (10.8) 30 (81 .1) 37 P=0.217 
Staged 
I 1 (4.0) 6 (24.0) 18 (72.0) 25 
II 9 (23.1) 4 (10.3) 26 (66.6) 39 
Ill 0 (0) 3 (27.3) 8 (72.7) 11 
IV 0 0 0 0 P=0.082 
ER 
Negative 2 (12.5) 2 (12.5) 12 (75.0) 16 
Positive 10(11.4) 16(18.0) 63 (70.8) 89 P=0.891 
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Table 5 continued: Correlation analysis between relative MI-ERoc staining in breast 
carcinoma and clinicopathological parameters using the Allred Scoring 
System 
MIER1 Expression:a Tumor Allred Score vs. Normal Allred Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total 
PR 
Negative 3 (10.8) 2 (7.1) 23 (82.1) 28 
Positive 9 (11 .8) 15(19.7) 52 (68.4) 76 
HER2/neu statuse 
Negative 10(13.5) 15 (20.3) 49 (66.2) 74 
Positive 1 (6.7) 0 (0) 14 (93.3) 15 
avalues are listed as number of subjects, with percentage listed in brackets. 
b P- value; Chi-square analysis (X') (Pearson's test, two-tailed, 95% Cl) , statistical significance is assumed 
when P < 0.05 
c Modified Scarff-Bioom-Richardson grading system 
d FIGO staging system 
P-valueb 
P=0.300 
P=0.086 
eHer2/neu status was determined through IHC: O=negative (no staining present), 1 +=negative (Weak/barely perceptible 
membrane staining), 2+=Borderline results/case referred for FISH analysis (weak to moderate complete membrane 
staining), 3+=positive (strong complete membrane staining) 
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Table 6: Correlation analysis between relative MI-ERoc staining intensity in breast 
carcinoma and clinicopathological parameters 
MIER1 Expression:a Tumor Intensity Score vs. Normal Intensity Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total 
Age 
<50 9 (29.0) 6 (19.4) 16 (51 .6) 31 
>=50 11(13.9) 26 (32.9) 42 (53.2) 79 
Age 
<=44 8 (40.0) 5 (25.0) 7 (35.0) 20 
45-64 6 (11 .3) 16 (30.1) 31 (58.4) 53 
>=65 6 (16.2) 11 (29.7) 20 (54.1) 37 
Tumor Size (TNM) 
T1 11(18.7) 17 (28.8) 31 (52.5) 59 
T2 7 (16.6) 11 (26.1) 24 (57.1) 42 
T3 and T4 2 (22.2) 4 (44.5) 3 (33.3) 9 
Tumor Size (Categorical) 
<=2 em 11(18.6) 17 (28.8) 31 (52.6) 59 
>2 em 9 (17.6) 15 (29.4) 27 (52.9) 51 
Lymph Node Involvement 
No 8 (18.6) 15 (34.9) 20 (46.5) 43 
Yes 4 (12.5) 9 (28.1) 19 (59.4) 32 
Lymph Node Status (TNM) 
NO 8 (18.6) 15 (34.9) 20 (46.5) 43 
N1 4 (16.0) 8 (32.0) 13 (52.0) 25 
N2 0 (0) 0 (0) 6(100.0) 6 
N3 0 (0) 1 (100.0) 0 (0) 1 
Gradec 
1 7 (23.3) 10 (33.4) 13 (43.3) 30 
2 10 (23.8) 9(21.4) 23 (54.8) 42 
3 3 (8.1) 13 (35.1) 21 (56.8) 37 
Staged 
I 2 (8.0) 9 (36.0) 14 (56.0) 25 
II 10 (25.6) 9 (23.0) 20 (51 .4) 39 
Ill 0 (0) 3 (27.2) 8 (72.8) 11 
IV 0 0 0 0 
ER 
Negative 2 (12.5) 4 (25.0) 10 (62.5) 16 
Positive 17 (19.1) 25 (28.0) 47 (52.9) 89 
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P-valueb 
P=0.364 
P=0.365 
P=0.618 
P=0.861 
P=0.833 
P=0.677 
P=0.382 
P=0.239 
P=0.194 
Table 6 continued: Correlation analysis between relative MI-ERoc staining intensity in 
breast carcinoma and clinicopathological parameters 
MIER1 Expression:a Tumor Intensity Score vs. Normal Intensity Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total 
PR 
Negative 3 (10.7) 6 (21.4) 19 (67.9) 28 
Positive 16 (21.0) 22 (28.9) 38 (50.0) 76 
HER2/neu statuse 
Negative 17 (23.0) 22 (29.7) 35 (47.3) 74 
Positive 1 (6.6) 4 (26.7) 10(66.7) 15 
3Values are listed as number of subjects, with percentage listed in brackets. 
b P- value; Chi-square analysis ('~;>) (Pearson's test, two-tailed, 95% Cl) , statistical significance is assumed 
when P < 0.05 
c Modified Scarff-Bioom-Richardson grading system 
d FIGO staging system 
P-valueb 
P=0.125 
P=0.388 
eHer2/neu status was determined through IHC: O=negative (no staining present), 1 +=negative (Weak/barely perceptible 
membrane staining), 2+=Borderline results/case referred for FISH analysis (weak to moderate complete membrane 
staining), 3+=positive (strong complete membrane staining) 
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Table 7: Correlation analysis between the proportion of MI-ERoc positively-stained cells in 
breast carcinoma and clinicopathological parameters 
MIER1 Expression:a Tumor Proportional Score vs. Normal Proportional Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total P-valueb 
Age 
<50 5 (16.1) 12 (38.7) 14 (45.2) 31 
>=50 9 (11.4) 26 (32.9) 44 (55.7) 79 P=0.536 
Age 
<=44 4 (20.0) 6 (30.0) 10(50.0) 20 
45-64 6 (11.3) 16 (30.2) 31 (58.5) 53 
>=65 4 (10.8) 16(44.2) 17 (45.9) 37 P=0.692 
Tumor Size (TNM) 
T1 6 (10.2) 21 (35.6) 32 (54.2) 59 
T2 6 (14.3) 14 (33.3) 22 (52.4) 42 
T3 and T4 2 (22.2) 3 (33.3) 4 (44.5) 9 P=0.916 
Tumor Size (Categorical) 
<=2 em 6 (10.1) 21 (35.7) 32 (54.2) 59 
>2 em 8 (15.7) 17 (33.3) 26 (51 .0) 51 P=0.704 
Lymph Node Involvement 
No 4 (9.3) 12 (27.9) 27 (62.8) 43 
Yes 5 (15.6) 17 (53.1) 10(31 .3) 32 P=0.378 
Lymph Node Status (TNM) 
NO 4 (9.3) 12 (27.9) 27 (62.8) 43 
N1 4 (16.0) 12 (48.0) 9 (36.0) 25 
N2 1 (16.7) 4 (66.6) 1 (16.7) 6 
N3 0 (100.0) 1 (0) 0 (0) 1 P=0.203 
Gradec 
1 6 (20.0) 12 (40.0) 12 (40.0) 30 
2 5 (11.9) 14 (33.3) 23 (54.8) 42 
3 3 (8.1) 12 (32.4) 22 (59.5) 37 P=0.199 
Staged 
I 1 (4.0) 7 (28.0) 17 (68.0) 25 
II 5 (12.8) 16 (41.0) 18(46.2) 39 
Ill 3 (27.2) 4 (36.4) 4 (36.4) 11 
IV 0 0 0 0 P=0.321 
ER 
Negative 3 (18.7) 5 (31 .3) 8 (50.0) 16 
Positive 9 (10.1) 32 (36.0) 48 (53.9) 89 P=0.343 
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Table 7 continued: Correlation analysis between the proportion of MI-ERoc positively-stained 
cells in breast carcinoma and clinicopathological parameters 
MIER1 Expression:• Tumor Proportional Score vs. Normal Proportional Score 
Clinical Parameters Less than Normal Equal to Normal Greater than Normal Total 
PR 
Negative 5 (17.9) 7 (25.0) 16 (57.1) 28 
Positive 7 (9.2) 29 (38.2) 40 (52.6) 76 
HER2/neu statuse 
Negative 8 (10.8) 27 (36.5) 39 (52.7) 74 
Positive 2 (13.3) 3 (20.0) 10 (66.7) 15 
Values are listed as number of subjects, with percentage listed in brackets. 
b P· value; Chi-square analysis (X') (Pearson's test, two-tailed, 95% Cl) , statistical significance is assumed 
when P < 0.05 
c Modified Scarff-Bioom-Richardson grading system 
d FIGO staging system 
P-value• 
P=0.093 
P=0.768 a 
eHer2/neu status was determined through IHC: O=negative (no staining present), 1 +=negative (Weak/barely perceptible 
membrane staining), 2+=Borderline results/case referred for FISH analysis (weak to moderate complete membrane 
staining), 3+=positive (strong complete membrane staining) 
110 
3.4 Number Cases used from the TMAs 
Due to the inherent nature of TMAs, some cases could not be assessed. Cores 
missing from the TMA upon purchase and cores lifting off the slide during staining (more 
specifically during antigen retrieval) are reasons why some cases could not be evaluated. 
Cores which contained an insufficient amount of relevant tissue were also excluded from 
the assessment. Table 8 illustrates the categorical breakdown of the number cases used in 
this study. 
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Table 8 Categorical breakdown of the number of cases used in this study: 
TMAs, WTS of breast tumor, and WTS of normal breast 
CATEGORY TMAs WTS: WTS: 
PURCHASED AS ESSED BREAST T MOR CASES NORMAL BREAST CASES 
NORMAL 204 180 85 46 
HYPERPLASIA 91 81 
DC IS 78 71 
ILC 102 99 
IDC 343 325 85 
LN METASTASES 16 16 
( IOC TUMORS) 
TOTALS 
NORMAL CASES ASSESSED = 311 
IDC CASES ASSESSED = 410 
MATCHED 
(TUMOR AND ADJACENT NORMAL) = 143 (58 TMA + 85 WTS) 
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3.5 MI-ERla Expression Pattern in Normal Breast and Invasive Ductal 
Carcinoma Tissue 
The initial part of this study involved assessing of the expression pattern of Ml-
ERa in normal and tumor breast tissue. In normal breast tissue, Ml-ERl a was 
predominantly observed in the ductal epithelial cells (Figure 26). Staining within the 
flattened, discontinuous myoepithelial cell layer, which surrounds the ductal epithelial 
cells, was difficult to discern. However, those few which could be assessed were either 
negative or had weak, focal cytoplasmic staining (Figure 26D). Also notable, was the 
absence, or weak cytoplasmic expression, ofMI-ERla expression within the vascular 
endothelial cells (inset ofFigure 26B) and the stromal cells. MI-ERla expression pattern 
within the invasive ductal carcinomas was similar to that of normal breast tissue. In that, 
staining was observed within the tumor cells (derived from ductal epithelium), whereas 
expression in stromal cells was either absent or weak (Figure 26 0-L). 
The intensity level ofMI-ERla expression within both the epithelial cells ofthe 
normal ducts and within the neoplastic cells ofthe breast tumor was variable. In that, the 
intensity level in the normal epithelial cells ranged from absent to weak, moderate or 
strong with no one prominent level; this observation was also noted for the breast tumor 
cel ls. 
It was also recognized when comparing the staining intensity level of that in the 
normal ducts to that of the lobules, within a single specimen, that there was no observable 
difference between the two (Figure 27). The intensity of staining observed within the 
ducts (Figure 27 A, C, E) is indistinguishable from that observed within the lobule (Figure 
27B, D, F). The intensity level, in both the nuclei and the cytoplasm, was either negative 
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or a range between mild to strong. Indicating that microscopically, MI-ER la appears to 
be equally expressed in the lobule and the ducts of normal breast tissue. 
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Figure 26 Expression pattern of MI-ERla in normal breast tissue and invasive 
ductal carcinoma tissue 
A-C, low magnification (4X): 
Representative examples of MI-ERla expression pattern within normal breast tis ue; it i 
observed in the ductal epithelial cells with little or no expression in the stromal ceJJs. The 
inset in B shows a higher magnification (40X) of the blood vessel, indicated by the long 
arrow, which demonstrates the weak staining observed within majority of the endothelial 
cells (arrowhead). 
D-F, High Magnification (40X): 
Examples of normal ducts illustrating both nudear MI-ERla staining (arrows) and 
negative nuclei (arrowheads). A myoepithelial cell which ha positive cytoplasmic 
staining and negative nuclei is marked by an M. A stromal ceJJ which is negative for MI-
ERla is indicated by an S. 
G-1, low magnification (4X): 
Representative examples of primary invasive ductal carcinoma. 
J-L, High Magnification (40X): 
Invasive ductal carcinoma samples exemplifying the exclusive cytopla mic expression of 
MI-ERla (brown staining) and negative nuclei (blue stain). 
The scale bar for A-C and G-1 is 250)-tm and 25)-tm for D-F, J-L and inset in H. 
115 
Normal 
Tumor 
116 
Figure 27 
Duct Lobule 
Staining intensity level of MI-ERla between normal breast ducts and 
lobules is indistinguishable 
Low to high magnifications of a repre entative sample of normal brea t tis ue stained 
with the anti-MIER 1-a antibody. Staining within breast lobules i illu trated panels B, D 
and F wherea panels A, C and E represent taining of breast duct from the arne sample. 
Note the presence of both positively stained nuclei (arrows) and negatively rained nuclei 
(arrowheads) within the lobule and the duct. The strong staining intensity within the 
nucleus is evident and the cytoplasm i moderately stained. The cale bar i lOOf..Lm for A 
and B (25X), 50f..Lm for C and D (SOX) and 25f..Lm forE and F (l OOX). 
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3.6 
3.6.1. 
Shift in Subcellular Location of MI-ERla from the Nucleus to the 
Cytoplasm 
Subcellular Localization ofMJ-ERla is Predominantly Nuclear in Normal 
Breast Tissue, but Cytoplasmic within JDC 
Samples of both WTSs and TMAs were analyzed for the subcellular 
localization ofMI-ERla in matched cases. Matched cases are samples of breast tumor 
that also contain adjacent normal breast epithelium. Eighty-five WTSs of matched IDC 
and adjacent normal breast tissue were used in the Allred Scoring assessment. Fifty-eight 
cases of matched tumor and adjacent normal breast from the TMAs were also used in this 
assessment. 
In this analysis, the result of each case was assigned to one of three following 
categories; those having nuclear staining only, cytoplasmic only or those which have both 
nuclear and cytoplasmic staining. It was noted upon review of these results that all of the 
positively stained samples had some cytoplasmic staining and as such the categories were 
reduced to 2; those which had nuclear staining and those that did not. 
When comparing the results from cases of normal breast to that ofiOC, the 
results were conspicuous. In that, a marked differential existed for the percent of nuclear 
stainjng observed within the normal compared to that ofiOC; 72.3% versus 4.4%, 
respectively (P<O.OOOI; Figure 28A). The majority of the normal samples had both 
nuclear and cytoplasmic staining (Figure 29A, 29C and 29E and Figure 260-F), whereas 
majority of the TOC cases had mainly cytoplasmic positivity (Figure 29B, 290, 29F and 
Figure 261-L). There was also a difference in the proportion of positive nuclei within a 
sample of normal breast tissue compared to that of IDC; greater than 50% of the nuclei 
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within normal breast cells were positive, however, IDC cells had less than 10% of 
positively stained nuclei. 
Correlations with clinicopathological parameters could not be carried out as there 
were not enough cases within each category for statistical analysis. For example, for 
tumor grade the majority of cases fell into the moderately differentiated category, and 
again a 2cm - Scm tumor size (T2) was most prevalent among all cases. 
119 
Figure 28 A shift in the localization of MI-ERla from the nucleus to the 
cytoplasm in the progression from normal breast and pre-invasive 
breast sub-types to breast carcinoma 
Panel A provides evidence that the percent of cases having positive nuclear staining 
decreases in the progression from normal to non-infiltrating breast abnormalities 
(hyperplasia and DCIS) to an invasive phenotype such as IDC. The percentage of DCIS 
samples having nuclear staining lies intermediate to that of the normal and IDC ca es. 
Panels B and Care cases of matched IDC and adjacent normal tissue from TMAs and 
WTSs, respectively. 
Data gathered from taken from assessment of WTSs of breast carcinoma (containing 
adjacent normal breast tissue), WTSs of normal breast (no history of breast carcinoma) 
and TMAs. The percentage of each ample expressing nuclear staining is shown along 
with the 95% confidence intervals. The number of samples for each category is shown 
above each bar. A** indicates that the P $0.0001. 
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Figure 29 Localization of MI-ERla is predominantly nuclear in normal breast 
and cytoplasmic in breast carcinoma 
An example of the staining pattern observed within matched cases of IDC and adjacent 
normal brea t tissue. Panels A, C and E illustrate the positive nuclear staining in adjacent 
normal breast from a case ofiDC (panels B, D and F) where the expression ofMI-ER1a 
is exclusively cytoplasmic. Negative and positive nuclei are indicated by arrows and 
arrowheads, respectively. The scale bar for A and B (25X) is 100!-lm, 50!-lm for C and D 
(SOX), and 25!-lm forE and F (lOOX). 
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3.6.2 Nuclear MI-ERla was Absent in Cases ofiLC and in IDC from Patients 
with LN Metastases 
Infiltrating lobular carcinoma also had a significantly marked reduction in the 
percent of cases with nuclear staining, 25.3%, when compared to that of normal breast 
tissue (72.3%, P<O.OOOl, Figure 28A). More specifically, staining in ILC cells was 
primarily cytoplasmic (Figure 30A-C) and the staining intensity within these samples was 
similarly to that for IDC, either negative or within the range of weak to strong. 
When comparing nuclear positivity within the normal to that of IDC cases 
having LN metastases, the results were similar to that observed when normal breast was 
compared to IDC cases without metastases. Only 6.3% of IDC cases (with LN 
metastases) had nuclear staining; which was statistically significant from that of the 
72.3% of normal breast cases which had nuclear staining (P<O.OOOl , Figure 28A, Figure 
30D-F). The percentage ofiDC cases, with LN metastases, having nuclear staining was 
similar to that ofiDC without LN metastases (P = 0.5009, Figure 26A). 
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Figure 30 Expression of MI-ERla in cases of ILC and ILC with LN metastases 
Illustrated in panels A-C are cases of ILC, in which the majority of the cases have 
cytoplasmic MI-ERla expression. Panels D-F are cases of IDC that have LN metastases; 
localization of MI-ERla is predominantly cytoplasmic which is similar to that of IDC 
without LN metastases. The single-Wing of cells, a classic pathological identifier for ILC, 
is marked by arrows in panels B and C. Negative nuclei are indicated by arrowheads. 
Scale bar is lOOJ.!m for panels A and B (25X), 50J.!m forB and E (SOX) and 25J.!m for C 
and F (lOOX). 
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3.6.3 Percentage of DCIS Cases having Nuclear Staining falls between that of 
the Normal Breast and that for IDC 
Ductal Carcinoma In Situ, a non-infiltrating breast lesion, has the potential to 
develop into or recur as an invasive breast carcinoma; a phenomenon which heavily 
depends on the extent of the lesion and the treatment used to resolve the DCIS (Yen et 
al. , 2005). 
Seventy-one cases ofDCIS were evaluated for subcellular localization ofMI-
ERla.. Thirty-six of these cases (50.7%) had nuclear staining; a value which lies 
intermediate to that ofthe normal breast (72.3%) and that of the IDC (4.4%, P = 0.0001 , 
Figure 28A). The staining intensity of DCIS cases ranged from weak to strong, with 
majority of cases displaying a strong expression of MI-ERl a.. As illustrated in Figure 31 , 
MI-ERl a. localization scores for all DCIS cases comprised of an equal distribution of 
both categories: approximately 50% had exclusive cytoplasmic staining (Figure 31 A-C) 
with the remaining cases having both nuclear and cytoplasmic staining (Figure 31 D-F). 
To determine if clinicopathological parameters, namely lesion size or nuclear 
grade, correlates with DCIS cases which have nuclear staining and those that lack nuclear 
staining, a correlation analysis was attempted. Unfortunately, this could not be carried out 
as the clinical data was either unavailable (lesion size) or there was not enough cases in 
each category within a paran1eter such as grade. For the TMA DCIS cases, 2 1 cases were 
nuclear grade II, 9 cases were nuclear grade I, 9 cases were nuclear grade III; for the 
remaining cases of DCIS the grade was not available. 
Four cases of comedo DCIS, a specific subtype ofDCIS, were also stained 
with the anti-MI-ERla. antibody. While the case number is too low to infer any 
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significant conclusions, it was noteworthy that all four cases presented with only 
cytoplasmic expression ofMI-ERla. A representative case ofthis result is illustrated in 
Figure 31 G-1. 
Four cases ofLCIS were also included in the TMAs and stained with the anti-
MIERla antibody, however no one category of localization pre-dominated. In that, 2 
cases had cytoplasmic only staining and 2 cases had nuclear and cytoplasmic staining. 
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Figure 31 Localization of MI-ERla in DCIS and comedo-DCIS 
The percent of cases having nuclear MI-ER J a in DCIS falls in between that for normal 
and IDC; approximately half the cases have nuclear positivity. Panels A-C shows a 
representative case lacking nuclear MI-ERla and panels D-F shows a representative case 
where MI-ERla is expressed within the nucleus. Exclusive cytoplasmic localization of 
MI-ERla in a case of comedo-DCIS is illustrated in panels G-I. Positive and negative 
nuclei are indicated by arrows and arrowheads, respectively. In panel G, "Necrosis" 
indicates an area of central necrosis, a typical feature of comedo-type DCIS. In addition, 
microcalcifications are also observed microscopically in comedo-DCIS and such areas are 
indicated in panel H with an "M". Scale bar is lOOflm for panels A, D and G (25X), 50flm 
for panels B, E and H (50X) and 25flm for panels C, F and I (IOOX). 
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3.6.4 Subcellular Localization of MJ-ERla in Breast Hyperplasia Cases is 
Strikingly Similar to that of Normal Breast Samples 
Eighty-one cases of non-atypical hyperplasia (atypical having a more abnormal 
pattern of growth) were stained with the anti-MI-ERla antibody and 62 (76.5%) ofthese 
cases had nuclear expression, a result similar to that of normal breast tissue (P = 0.8831 , 
Figure 28A and Figure 32A-D). 
Staining intensity, as in normal breast tissue, was negative, weak, moderate or 
strong, with majority of the cases having a moderate expression level (Figure 32). 
Also noteworthy was that 8 of the 10 atypical hyperplasia cases from one of the 
TMAs had cytoplasmic staining; the other two cases could not be assessed. 
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Figure 32 
Case #1 Case #2 
Localization of MI-ERla in cases of breast hyperplasia is 
predominantly nuclear 
Two representative examples of breast hyperplasia demon trating nuclear and 
cytoplasmic MI-ERla expression. Positive and negative nuclei are marked by 
arrow and arrowheads, re pectively. Asterisks in panels A and D indicate areas 
which have an increase in the number of abnormal cell ; a trait which is used to 
identify breast hyperplasia. The scale bar is 50j..lm for panel A and B (SOX) and 
25 j..lm forD and F (lOOX). 
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3.6.5 A Differential in Subcellular Localization exists between Matched Cases of 
lDC and Adjacent Normal Breast Tissue 
To establish that the difference in the subcellular localization ofMI-ERla 
between normal breast tissue and IDC was not due to individual patient differences, 
nuclear staining in IDC cases was compared with that of the adjacent normal breast tissue 
(matched cases). Eighty-five WTSs ofiDC cases (Figure 28C), having adjacent normal 
breast tissue, as well as 58 TMA cases ofiDC (Figure 28B) with matched cores 
containing adjacent normal breast tissue were examined. Matched cases of WTSs and 
TMAs give results similar to that for the unmatched cases described in Section 3.5.1. In 
that, the majority ofthe breast tumors lacked nuclear staining (WTSs: 5.9%, TMAs: 
12.1 %), whereas the adjacent normal tissue displayed nuclear staining (WTSs: 85.9%, 
TMAs: 74.1 %, Figure 28B and 28C, Figure 27). 
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4. DISCliSS!ON 
This study was done to assess the pattern of expression, the level of expression 
and the subcellular localization ofMIERla, a novel ER co-regulator, in both normal 
breast tissue and breast cancer tissue. 
Previous studies have demonstrated that MI-ERl a has the capacity to act both 
as a co-repressor and a co-activator (Ding et al., 2003; Paterno et al., 1997; Paterno et al. , 
1998). Recently, we demonstrated, that MI-ERla interacts with ERa in vivo (McCarthy et 
al., 2008). It was also shown that induced expression ofMI-ERla, in a T47D breast 
carcinoma cell line, leads to a reduction of anchorage independent growth (McCarthy et 
al. , 2008). Together, these results infer that MI-ERla plays a role in ER-dependent cell 
proliferation. The latter 2 sets of results are illustrated in Appendix B. 
4.1 Allred Assessment Revealed that there is No Significant Correlation 
Between MI-ERla Expression and Mammary Clinicopathological 
Parameters 
The Allred Scoring System was used to determine if a relationship existed 
between the level of Ml-ERla and clinicopathological parameters. No one category, 
tumor score less than normal, greater than normal or equal to normal, dominated and 
neither of which correlated with clinicopathological parameters. A study reviewing the 
same parameters but with a larger sample size, with the hope of obtaining an even 
distribution of stage I-IV cases as well as more Her2/neu positive cases, is warranted 
since the probability associated with each of these paran1eters approached significance at 
P = 0.082 and P = 0.086, respectively. 
132 
4.2 Proteins that have a Shift in its Subcellular Localization may Contribute to 
the Progression of Breast Carcinoma and Impact the Therapeutic 
Response 
A decrease in the number of cases that have nuclear MI-ERla expression, as 
one compares the pre-invasive types to the invasive carcinomas, demonstrates its 
potential role in the progression of an invasive breast carcinoma. 
Willie the literature demonstrates opposing views, some researchers still 
believe that normal cells can advance to an invasive carcinoma sequentially; 
simplistically, they can become hyperplastic, then develop into a DCIS/LCIS lesion and 
finally an invasive carcinoma. A model proposed from the results of this study, in 
conjunction with work carried out by M. Savicky and C. Mercer (Appendix B), is that 
during the progression from a normal phenotype to DCIS and then to IDC, MI-ERl a is 
shuttled from the nucleus to the cytoplasm. This shift in localization is what prevents MI-
ERI a from exerting its genomic effects through its interaction with the ERa. However, it 
is also possible that this shift allows for the cytoplasmic interaction between MI-ERl a 
and the ERa where it acts as a co-activator to enhance ERa non-genomic activities, such 
as cell growth stimulation through signal transduction pathways, as seen with MT A I 
(Kumar, Wang, Mazumdar, Talukder, Mandai, Yang, et al. , 2002) 
There are many examples whereby a shift in the localization of a protein can be 
associated with the development of a carcinoma, as well as the tumor' s clinical response 
to therapy. For example, an increase in nuclear YB-1 is associated with up-regulation of 
the P-glycoprotein; a protein known to increase the likelihood of chemotherapy resistance 
in many cases of breast carcinoma (Fujita et al., 2005). From this, one would infer that 
133 
r-------------------~---------------------------- --
nuclear YB-1 connotes a poor prognosis for women diagnosed with breast carcinoma and 
for whom chemotherapy is a part of their treatment regime. Again, in another study using 
manunalian cancer cell lines to investigate the role of Apoptin (produced by the VP3 gene 
of the chicken anemia virus and known to induce cell death) in cancer development found 
that it was held in the cytoplasm and therefore could not exert its apoptotic effects. 
Casteel, et al. (2008) found that PKGs (Type I cGMPs-dependent protein kinases) which 
translocates to the nucleus to regulate gene expression are found to be anchored by the 
binding of a specific protein (inositol 1 ,4,5-triphosphate (IP(3)) receptor-associated 
cGMP kinase substrate (IRAG)) and hence retained within the cytoplasm; an event that 
prevents PKGs ability of exerting its transactivational influences. Metastatic tumor 
antigen 1 (MT A 1) is a protein whose expression is associated with an increased risk for 
development of invasive carcinomas and metastases (Nawa, Nishimori, Lin, Maki, Moue, 
Sawada,Toh, Fumitaka, &Nicolson, 2000). Kumar et al. (2002) found that metastatic 
tumor antigen 1 (MTAI), which localizes to the cytoplasm, anchors ERa in the cytoplasm 
where it can enhance the non-genomic effects of ERa. In this study it was shown that 
when a specific portion of the MT A 1 gene was deleted, there was loss of its co-repressor 
activity, its interaction with ERa and is associated with restoration of nuclear ERa 
expression (Kun1ar et al. , 2002). 
From this, one might suggest that MI-ERa becomes exported from the nucleus 
or anchored in the cytoplasm, where it can no longer act as a co-repressor or ER-
dependent proliferation, as it progresses from normal an invasive breast phenotype. 
However, it is also possible that MI-ER1a is sequestered in the cytoplasm during the 
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progression to an invasive carcinoma, where it acts to promote the proliferative activities 
of ERa. 
4.3 Absence of a Differential in the Expression Levels of MI-ERla Between 
Normal and Tumor 
There was no differential in the level of expression of MI-ERI a between 
nonnal and tumor. Some cases had an equal expression of MI-ERI a in the tumor and 
adjacent normal, while others either had higher or lower expression in the tumor versus 
normal. [n a previous study by Paterno et. al. (1998) using PCR mRNA expression 
analysis, it was shown that mi-er 1 was expressed at higher levels in breast tumor tissue 
than that of normal breast tissue. This inconsistency can be explained through the fact that 
its expression in normal breast tissue if limited to ductal epithelial cells, but in a tumor it 
is expressed in every cell. Therefore, the number of cells expressing mi-er 1 mRNA in the 
normal san1ple would be expected to be lower when compared to the same volume of 
tumor. 
4.4 MI-ERla Localization in DCIS Cases may be a Determinant of in situ 
Recurrence and or Progression to an Invasive Carcinoma 
In this study, the results of the DCTS subcellular localization analysis revealed 
that only half of the cases lack nuclear MI-ERl a expression. However, majority of the 
IDC cases had loss of nuclear MI-ERla. Not all cases ofDCIS, following treatment, have 
an in silu recurrence or progress to an invasive carcinoma. However, those that have 
DCIS are at an increased risk for such. Taken together, these raise important questions 
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regarding the potential role ofMI-ERla in the recurrence ofDCIS and/or if it promotes 
the progression to IDC. 
One of the things that a pathologist takes into account when determining the 
possible risk of recurrence for a patient having been diagnosed with DCIS is the margin 
of resection. This margin is defined as the distance between the perimeter of the removed 
lesion and the normal area that was removed. Vargas, et al. (2005) (2008) found that 
individuals whose lesion's margin of resection were less than or equal to 2mm (which are 
considered "close" or "positive" margins), or if the lesion was of high grade (poorly 
differentiated), there is a higher risk for breast cancer. Rashtian, et al. (2008) also found 
that small tumor margins and high grade lesions were associated with higher risk for local 
recurrence. In addition, they found that comedo DCIS lesions which have a central 
necrotic area increase the risk of local recurrence. Another recent study by Korourian, et 
al. (2008), determined the tumor-associated carbohydrate antigen (T ACA) expression and 
correlated it with things such as tumor size, nuclear grade and ER and PR status. They 
found a significant correlation between T ACA expression and high nuclear grade. From 
this, they predicted that TACA might contribute to the development of a higher-grade 
DCIS lesion and disease recurrence. One other study, using immunohistochemical 
analysis, found that expression of COX-2 and PPARy in DCIS lesions have opposite 
associations with recurrence. COX-2 is an enzyme involved in prostaglandin synthesis; 
prostaglandins are fatty-acid derivatives that contribute to inflammation and immune 
response effects. PPARys play a role in cell differentiation, inflammation and lipid 
metabolism. High expression of COX-2 was found to be associated with recurrence, 
whereas nuclear PPARy expression in DCIS lesions appeared to have a protective effect. 
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This, together with the data from this study, one might predict that a specific 
pattern of MI-ER 1 a subcellular localization within a DCIS lesion might contribute to 
and/or be prognostic for recurrence of an in situ carcinoma or an invasive phenotype. 
Although there are no clear tests that distinguish which cases ofDCIS are at an 
increased risk for developing a recurrence, there is a specific DCIS subtype that imposes 
a greater malignant potential than others, namely, comedo DCIS. This type ofDCIS has a 
specific histological feature that distinguishes it from others, and that is the presence of a 
central necrotic area. One study proposes that this necrotic area arises as a result of 
apoptosis due to the influence of both environmental and internal genetic insults. These 
apoptotic events permits elimination of both myoepithelial cells and luminal cells and 
allows for expansion of the apoptotic-resistant cancer cells (Shekhar, et al., 2008) 
This study had four cases of comedo-DCIS; all of which had loss of nuclear MI-
ER 1 a. In relating this result to the above information, it is possible that loss of nuclear 
MI-ERla might be one such internal alteration which influences a comedo DCIS cell to 
undergo apoptosis. 
4.5 IHC and TMA limitations 
Immunohistochemistry is an effective tool for evaluating the location and level 
of expression of proteins and one which has long been employed in both laboratory 
research and in clinical settings. However, this technique brings with it some limitations 
that need to be considered. One artifact that is common after performing IHC is the 
uneven staining of samples which is often due to poor fixation and hence non-uniform 
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antigen retrieval. In this study, attempts were made to control for this through exclusion 
of samples that were not appropriately fixed. 
The other issue is that maximum quantitative evaluation achieved through IHC 
is semi-quantitative and hence to quantitatively assess the protein, other assays such as 
those which combine digital imaging with fluorescence microscopy would need to be 
used. Fluorescent immunohistochemistry can be utilized to quantify light emitted from 
each cell within a paraffin tissue section. 
With regard to staining ofTMAs, it is essential to use a large sample size 
and/or compare the results to a few cases of whole tissue sections. Tumors are 
heterogeneous in nature and for this reason when taking a small core from a larger 
sample, any results from such may not be representative of what is going on in the whole 
tissue. In this study, a large number of whole tissue sections were utilized and analysis 
was compared to that of the TMAs. 
4.6 Future Directions 
A complete understanding of the mechanism ER-stimulated cancer cell growth 
is essential to the development of better treatment regimes for breast cancer, prognostic 
indicators and ideally the development of early detection/screening markers. 
This study has identified that MI-ERla does indeed play a role in this pathway. 
It has also established that one of the functional implications of an interaction between 
MI-ERla and the ERa is a reduction in ERa-mediated cancer growth. However, the 
mechanistic details of how this occurs should be investigated. Further to this, it would be 
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particularly important to determine how it is that MI-ER 1 a is either held in the cytoplasm 
or shuttled from the nucleus. 
Initially, it would be advantageous to use a protein microarray, which contain 
hundreds or thousands of human proteins fixed to an array. To this array one would apply 
the antigen of interest (MI-ERla) followed by a detection method such as fluorescence. 
Positive staining or fluorescence will indicate a protein-protein interaction involving the 
antigen of interest. Following this, one would review the properties of the other protein, 
to which the antigen of interest binds, and determine where it might be expressed (its 
localization) and what its function is; all of which could provide evidence as to the role 
MI-ERl a plays in ERa-mediated breast cell growth as well as its mechanism of 
localization. If it is determined that MI-ERla interacts with a cytoplasmic protein, then 
RNA interference can be utilized to see the functional effects of blocking this interaction. 
In this study there were 4 cases ofLCIS, 2 cases had nuclear and cytoplasmic 
staining and the other two had only cytoplasmic staining. While this number is low, it 
warrants further investigating through staining of a larger sample size to see if this pattern 
continues and is therefore similar to that of DCIS whereby approximately 50% of the 
samples lacked positive nuclear staining. 
To reiterate what was stated in the discussion, while 50% of the DCIS cases 
lacked nuclear staining, almost all ofthe IDC cases displayed loss of nuclear MI-ERla 
(95.6%). This is of particular importance since having DCIS is not a predetermining 
factor for development of IDC and currently there are no tests that can predict the 
outcome for patients with DCIS (Wiechmann & Kuerer, 2008). Therefore, it would be 
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important to conduct a study using a larger sample size of DCIS cases and determine if 
MI-ERla is a prognostic indicator. For this, one would obtain cases that had been 
diagnosed with DCIS approximately 15-20 years prior. These cases can be stained with 
anti-MI-ERal and localization results can be cross referenced with the categories ofthose 
who did develop IDC and those who did not to see if there is a correlation. Another 
possibility is to do a prospective study using a sample of patients who have had surgical 
removal of DCIS lesions, then staining these samples with anti-MI-ERI a , following them 
for a period of time to see if they develop IDC to determine if there is a correlation. The 
goal is to determine if there is a specific MI-ERI a staining pattern within DCIS lesions 
that can accurately predict ones risk for development of an invasive breast carcinoma. 
Using the same set of cases it would be important to determine if there is a correlation 
between the loss of nuclear MI-ER 1 a and 5 and 1 0-year survival time points. 
The advantage of using a larger sample size of invasive lobular carcinomas 
would be to see if there is a correlation between the staining pattern ofMI-ER1a in this 
carcinoma and clinicopathological parameters. In particular, it would be interesting to 
compare the expression pattern of Ml-ER 1 a in both ER positive and ER negative breast 
tumors. It would also be useful to conduct a study, looking at the expression pattern of 
MIERla in special types of breast carcinoma such as Paget's disease and inflammatory 
breast cancer. In the current study there were not enough cases for each category of DCIS 
grade and hence a statistical analysis could not be carried out. Therefore, future studies 
should include DCIS cases for which the grade of the lesion is available. 
Ki-67 is often included in the pathological workup following removal of a 
breast lesion. It is a protein whose expression correlates with the mitotic index. A higher 
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mitotic index is associated with a higher neoplastic proliferation rate and hence a higher 
possibility of developing an invasive or metastatic carcinoma. Ki-67 is one of the 21 
genes included in the Oncotype OX test that is utilized throughout the US and in some 
areas of Canada. The Oncotype DX test enables physicians and the patient to learn more 
about the biological activity of their breast tumor. More specifically, it is a test that 
assesses the expression of 16 genes known to be associated with breast cancer, as well as 
5 control genes. The results of the test are reported as a quantitative recurrence score; a 
number between 0 and 100. The recurrence score allows physicians to predict both the 
risk of recunence in node-negative, ER positive, early stage (I or II) invasive breast 
cancer patients, as well as their response to chemotherapy. 
IGFBP-rPl is a protein whose expression has been previously shown to be 
associated with progression from an in situ lesion to IDC (Wiechmann & Kuerer, 2008). 
Correlating the loss of nuclear MI-ERla with either Ki-67 or IGFBP-rPl may provide 
insight into the role ofMI-ERla in the development ofiDC. 
To date, the molecular mechanisms involved in the progression of comedo 
DCIS cells to that which is invasive, are not yet known. Comedo DCIS is a more 
aggressive form ofDCIS (Maxhimer et al. , 2005). In this study there were 4 such cases 
and all ofwhich had loss of nuclear MI-ERla. Therefore staining a larger sample size of 
various DCIS subtypes to see ifthe loss ofMI-ERla is associated with more aggressive 
DCIS subtypes. 
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4.7 Conclusions 
Evidence that MI-ERla functions as an ERa co-repressor was provided 
through experiments demonstrating the ability ofMI-ERla to physically interact with the 
ERa and that its overexpression results in a decrease of E2-stimulated breast cancer cell 
growth (McCarthy et al., 2008). 
Estrogen receptor-stimulated breast cell growth requires interaction between the 
ERa and a number of co-regulatory molecules; such molecules have been the target of 
many therapeutic drugs designed to control the tumor growth as well as those aimed at 
preventing tumor recurrences. Several ERa co-regulatory molecules have been identified, 
some of which have been confirmed to act as co-repressors of ERa activity (Banialunad, 
2005; Hall & McDonnell, 2005). These include NCoR and SMRT, both of which are 
ligand-independent co-repressors, as well as MTA 1-3 (J.D. Chen & Evans, 1995; Horlein 
et al., 1995; Manavathi & Kumar, 2007). 
The results of this study confirm that a shift ofMI-ERla from the nucleus to 
the cytoplasm is associated with the progression to an invasive lobular or ductal breast 
carcinoma. Hence, a loss of nuclear MI-ERla may be a contributing factor in the 
development of an invasive breast carcinoma. In this regard, MI-ERla represents a 
promising breast cancer prognostic marker and possibly a therapeutic target. 
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Non-proliferative Breast Changes 
These group of breast changes are not associated with an increased risk for the 
development of breast carcinoma. Complex fibroadenomas, which is a sociated with an 
increased risk of future breast cancer development, was included under this section so that 
it could be simultaneously compared to the non-complex fibroadenomas. Also, included 
in this section are moderate and florid hyperplasia which are associated with an increased 
risk for developing breast cancer. Again, these are included in this section to aJJow for a 
simultaneous comparison to that of mild hyperplasia. 
A: Duct ectasia is usually present in post-menopasual women and is characterized by a 
dilation of the larger ducts. The dilated ducts are marked by the presence of inspissated 
debris that is both acellular and contains evidence of an inflammatory reaction. Due to the 
presence of fibrosis around the ducts, a palpable mass is sometimes detected and mistaken 
for breast cancer. 
B: Cysts can develop through the dilation of acini , which are lined by a flattened 
epithelium or cuboidal cell layer and vary in size, shape and number present. As with duct 
ectasia, it is not associated with an increased risk for breast cancer (Table 1). 
C: Apocrine change, another non-proliferative condition refers to cysts that are lined 
with columnar epithelium that resembles that of normal apocrine sweat glands. These 
cells also contain an eosinophilic ("pink-staining") cytoplasm. 
D: Adenosis is another non-proliferative breast condition that is not as ociated with an 
increased risk in breast cancer development. It is an enlargement of lobules as a result of 
an increa e in the number of acini, however the structure of lobular unit p rsists. 
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E: Fibroadenomas are classified into two groups: Fibroadenomas without complex 
features and Fibroadenomas with complex features. Those those that present without 
complex features, are non-proliferative and not associated with an increased risk of 
developing breast cancer. Secondly, are those that are in direct contrast to the latter-
present with complex features, are classified as proliferative without atypia and are 
associated with an increased risk of breast carcinoma. Fibroadenomas are benign lesions 
that arise from both the stroma and the glandular epithelium. Histologically, the ducts 
appear as elongated and thinned which is surrounded by an expanded stroma and does not 
have any clinicopathological characteristics that increase the risk of developing breast 
cancer. However, those that are associated with complex features, such as cysts that are 
larger than 0.3cm, sclerosing adenosis (discussed in the next section), calcifications, 
papillary apocrine changes are associated with an increased the risk for developing breast 
carcinoma 1.5-2.0 fold (Lester, 2005). 
Proliferative Disease with Atypia 
A: Fibroadenoma with complex features-discussed in previous section 
B: Moderate and florid hyperplasia-discussed in previous section 
C: Sclerosing adenosis is an extension of adenosis mentioned in the previous section. 
In addition to the increase in the size of the lobular unit, through an increase in the 
number of acini , sclerosing adenosis arises when these acini are compressed and distorted 
in the central region of the lesion, but often dilated at the perimeter. 
D: Complex sclerosing lesions, often referred to as radial scars if greater than 1 Ornm, 
focal lesions that consists of a central region with small ducts embedded in a dense 
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fibrous stroma. Radiating from this central region are epithelial projections ("arms") 
which contain cysts and hyperplastic cells. These lesions may be mistaken for an invasive 
breast carcinoma on mammograms and histologic examination (Kennedy, Masterson, 
Kerin, & Flanagan, 2003 ; Lester, 2005). 
E: Papillomas can exist as a solitary growth within a large dilated duct, usually within 
the lactiferous sinus, or as multiple small papillomas that usually arise in the posterior 
regions of the ductal system. Papillomas are branched papillae (small projections) 
structures with fibrovascular cores, that are lined by both epithelial and myoepithelial 
cells. They can exist alone or co-exist with atypical ductal/lobular hyperplasia (discussed 
in following section). Ifthere are multiple papillomas, which may or may not co-exist 
with ADH or ALH, present there is a significantly higher risk for breast cancer 
development than when a single papilloma is associated with ADH or ALH (Lewis et al., 
2006) 
146 
APPENDIX B: 
Extra Figures from McCarthy et. al. (2008) 
147 
Figure 1 
A 
B WB: 
Con mier1 a 
+ + 
2 3 4 
IP: ERa WB: 1VIier1a 
WB: IVIier1 a 
WB: ERa 
anti-ERa 
IP: anti-IVIier1a pre 
E2 + + 
ERa .... ,.-. 
2 3 4 
...,.IV1ier1 a 
...,.IVIier1a 
+ 
5 6 
Figure 1 MI-ERla interacts with ERa in vivo. 
(A) HEK293 cells were transfected with pcDNAJ-hera. and either pCS3+MT-
mierla (lanes 3 and 4) or control empty vector (lanes 1 and 2) and treated with 
vehjcle (lanesl and 3) or 10 nM E2 (lanes 2 and 4) for 3 h before extraction. Extracts 
were subjected to irnmunoprecipitation with anti-ERa (top panel) or loaded directly 
onto the gel (middle and bottom panels). Western blots were stained for MI-ERla 
(top and middle panels) or ERa (bottom panel). (B) Extracts from MCF-7 cells 
treated with vehicle (lanes 1, 3 and 5) or l 0 nM E2 (lanes 2, 4 and 6) were subjected 
to IP with anti-rruerla (lanes 1 and 2), pre-immune (lanes 3 and 4) or loaded directly 
onto the gel (lanes 5 and 6); Western blotting was performed with anti-ERa. 
[Work carried out by M. Savicky and published in McCarthy, et. al. (2008)]. 
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Overexpression of MI-ERla reduces anchorage-independent 
growth of T47D breast carcinoma cells. 
Control (TDc22)- or MI-ERla (TDa5 and TDa7)-expressing Tet-On T47D clones 
were cultured in 0.35% agarose, in the presence or absence of2 mg/ml_ l dox and in 
the presence or absence of 10 nM E2. Colonies were stained with crystal violet, and 
colony size was measured using an ocular micrometre. A minimum of six fields 
from each plate was analysed; the number of colonies larger than 100 rnrn in size, 
expressed as a percentage of the total number of colonies, was recorded for each 
treatment. (A) Representative fields for each treatment combination for each clone 
are shown. (B) Histogram showing the 
average values and error bars for three independent experiments, performed in 
duplicate. (C) Western blot analysis to verify dox-specific induction of MIERla 
expression. A representative blot of extracts from TDc22, TDa5 and TDa7 cells, 
cultured in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4 and 6) of 2 mg/ml 
dox, is shown. The position ofMI-ERla is indicated. 
[Work carried out by C. Mercer and published in McCarthy et. al. , (2008)] 
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Tissue and Fixation Processing Procedures 
When fixation is inadequate it can adversely affect both a pathologists' diagnosis and 
presentation of requested stains. Adequate fixation of a sample is also critical for its 
subsequent use in future investigations through either a patient's request for a second 
opinion or consultation work involving other hospitals or laboratory research methods 
such as inununohistochemistry (Lester, 2005; Parnell, 2008; Rosai & Ackerman, 2004). 
TMAs 
A Biochain Insitutue Inc. 
Normal tissues used in the construction of the TMAs were excised from death 
donors and tumors were removed during surgery. The tissue was fixed in formalin 
immediately after harvesting for varying times depending on the tissue, for a maximum of 
48 hours. The tissues are then serially dehydrated overnight through various grades of 
alcohol (50%, 70%, 80%, 90%, 100%), cleared in xylene and then embedded into a 
paraffin wax. 
B US Biomax Inc. 
Tissues removed during surgery were immediately fixed in a 10% neutral PBS 
buffered formalin, while post-mortem tissues are placed in fixative within six hours after 
removal. Both surgically removed and post-mortem tissues were fixed for 24 hours before 
placement in a Leica tissue processor. The processing involved dehydration through an 
alcohol gradient, clearing in xylene and paraffin embedding. 
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C CHTN 
Tissues used in the construction of the TMA were obtained from the University 
of Virginia Hospital. Tissues were removed during surgery or post-mortem and 
immediately fixed in zinc formalin (Z-fix, Anateach Ltd.) for 24 hours. The tissues are 
then processed in a Tissue Tek VIP 2000 (Sakura Finetek USA, Inc.), which involves the 
same steps as the previously described TMAs; dehydration followed by clearing in xylene 
and paraffin embedding. 
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Labeled Streptavidin-Biotin (LSAB) Method 
This kit relies on the strong binding affinity of Steptavidin for the vitamin 
biotin. Similar to Avidin, Streptavidin has four binding sites for biotin, but in contrast to 
avidin it has a more neutral isoelectric point and no carbohydrate moieties. The latter of 
which permits a reduction in non-specific binding (DakoCytomation, 2006). 
Biotinylated secondary antibodies binds easily to primary antibodies and serves 
as the link between the primary antibody and the strepavidin-peroxidase conjugate. In the 
end, because of the previously mentioned 4 biotin-binding sites on strepavidin, a single 
antibody is linked to multiple peroxidase molecules (Appendix C). 
Horseradish peroxidase (HRP) activity, isolated from the root of a horseradish 
plant, in the presence of an electron donor such as 3,3' - diarninobenzidinetrahydro-
chloride (DAB), results in an enzyme - substrate complex then oxidation of the electron 
donor (DakoCytomation, 2006). When DAB becomes oxidized it produces an insoluble 
brown end product. When performing IHC with the anti-MI-ERla antibody, it is this 
brown staining that is indicative for the presence ofMI-ERla. 
154 
A~ 
1\1\ 
Step I 
Primary Antibody 
Secondary Antibody 
I\/\ 
Tissue Antigen 
X Streptavidin 
• HRP 
t Biotin 
A~ 
1\1\ 
Step 2 
Labeled Streptavidin-Biotin (LSAB) Method 
A~ 
1\1\ 
Step 3 
The primary antibody is applied to the tissue section (Step 1) and is incubated overnight 
to allow binding to the tissue antigen. A biotinylated anti-mouse/rabbit secondary 
antibody is applied and attaches to the primary antibody. The biotinylated secondary 
antibody acts as a link between the primary antibody and the Streptavidin molecule; the 
latter of which has a high binding affinity for the biotinylated secondary antibody. 
(DakoCytomation, 2001) 
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1. 1% BSA/PBS, pH 7.4 
A powdered form of PBS which contains BSA was ordered from Sigma - Aldrich. 
Dissolve one sachet in lL of deionized water; which yields and 1% w/v ofBSA 
and a solution with a pH of7.4. 
2. Citrate Buffer 10mM 
Dissolve 1.92g citric acid in lL deionized water and adjust the pH to 6.0 using lN 
NaOH. 
3. PBS, pH 7.4 
A powdered form of PBS which when one sachet is dissolved in lL of deionized 
water yields a O.OlM PBS solution at a pH of7.4. 
4. Hematoxylin 
Combine 180g of aluminium ammonium sulfate dissolved in 1200ml water with 
12g hematoxylin dissolved in 75ml of 95% alcohol in a transparent glass bottle. 
Expose the mixture, unstoppered, to light and air for 1 month; filter into a second 
transparent bottle. Add 300ml glycerin and 300m! 95% alcohol. Allow solution to 
stand in light until colour is sufficiently dark before filtering into a dark glass 
bottle. Store for up to one month at room temperature in a dark glass bottle. 
5. Scott's Tap Water 
Add 3.5g sodium bicarbonate to lL of tap water and 20g magnesium sulfate to a 
second litre of tap water and store separately. Immediately prior to use combine, 
in a 50:50 ratio, each ofthe above solutions. 
6. 1% Acid Alcohol: 
To lL of70% Alcohol add lOmL of 12N HCI 
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